Recombinant baculovirus plasmid, recombinant baculovirus, detection kit and microfluidic channel system

By embedding recombinant manifestation protein genes and exogenous protein genes in baculovirus plasmids and combining with microflower system, efficient antigen or antibody detection is achieved, solving the high detection cost, cumbersome steps and weak signal in the prior art. Problem, suitable for a variety of biological detection applications.

WO2024230648A1PCT designated stage expired Publication Date: 2024-11-14SINGAPORE BIOCHIPLET MEDICAL AI PTE LTD +1
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/091254
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-08
Filing Date
2024-05-06
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

The existing disease detection technology has high cost, cumbersome steps, specificity and insufficient signal strength during the development and operation process, especially in applications related to antigen-antibody immune response.

Method used

Recombinant baculovirus plasmid, recombinant baculovirus and microflower system are used to embed recombinant manifestation protein genes and exogenous protein genes in baculovirus plasmids, and the detection of biological samples is carried out using the microflower system, combining antibodies and Capture layers for efficient antigen or antibody detection.

Benefits of technology

It reduces the development cost and operation steps of disease detection, improves the specificity and signal strength of the detection, and is suitable for the fields of disease diagnosis, health examination, pathogenic microbial identification and epidemiological investigation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024091254_14112024_PF_FP_ABST
    Figure CN2024091254_14112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a recombinant baculovirus plasmid, a recombinant baculovirus, a detection kit and a microfluidic channel system. The recombinant baculovirus plasmid comprises a baculovirus plasmid, a recombinant expression protein gene and an exogenous protein gene. The recombinant expression protein gene and the exogenous protein gene are located on the baculovirus plasmid. The recombinant expression protein gene comprises an expression protein gene and a reporter protein gene. The provided recombinant baculovirus plasmid is suitable for being inserted into a baculovirus gene and is contained within the recombinant baculovirus in a replicable manner. In addition, the recombinant baculovirus with the provided recombinant baculovirus plasmid can be used in the detection that is performed by the microfluidic channel system, and thus the detection kit using the recombinant baculovirus plasmid can be provided. In particular, in some examples, the detection kit using the provided recombinant baculovirus plasmid can be used for detection without the need for a secondary antibody.
Need to check novelty before this filing date? Find Prior Art

Description

Recombinant baculovirus plasmid, recombinant baculovirus, detection kit and microfluidic system Technical Field

[0001] The embodiments of the present invention generally relate to a recombinant technology, and more particularly to a recombinant baculovirus plasmid, a recombinant baculovirus, a detection cartridge, and a microfluidic system. Background Art

[0002] The baculovirus expression system uses baculovirus to produce foreign proteins, such as antigens or antibodies. Compared to Escherichia coli, Bacillus subtilis, or lactic acid bacteria, the baculovirus expression system is a eukaryotic expression system, so the proteins it produces are more similar to those produced by mammals. Consequently, baculovirus-based research and development has become increasingly popular in recent years.

[0003] Summary of the Invention

[0004] In view of this, the present invention provides a recombinant baculovirus plasmid, a recombinant baculovirus, a detection kit, and a microfluidic system for applying the recombinant baculovirus plasmid in detection.

[0005] According to a first aspect of the present invention, a recombinant bacmid is provided, comprising: a bacmid, a recombinant expression protein gene, and a foreign protein gene. The recombinant expression protein gene and the foreign protein gene are located on the bacmid. The recombinant expression protein gene comprises an expression protein gene and a reporter protein gene.

[0006] In some embodiments, the bacmid comprises: a right Tn7 transposon; a left Tn7 transposon; a first promoter located between the right Tn7 transposon and the left Tn7 transposon; and a second promoter located between the first promoter and the left Tn7 transposon; wherein the recombinant expression protein gene is located between the second promoter and the left Tn7 transposon, and the exogenous protein gene is located between the right Tn7 transposon and the first promoter.

[0007] In some embodiments, the exogenous protein gene is a transmembrane protein gene or a non-transmembrane protein recombinant gene.

[0008] In some embodiments, the exogenous protein gene is a transmembrane protein gene, and the transmembrane protein gene is an antigen gene.

[0009] In some embodiments, the antigen gene is selected from the group consisting of dengue virus antigen gene and Japanese encephalitis virus antigen gene.

[0010] In some embodiments, the antigen gene is selected from the group consisting of a pre-membrane protein (prM) gene, an envelope protein (E) gene, and a combination thereof.

[0011] In some embodiments, the exogenous protein gene is a non-transmembrane protein recombinant gene, comprising a non-transmembrane protein gene and a second expression protein gene, wherein the non-transmembrane protein gene is selected from the group consisting of an antibody, an antigen, a protein A, a protein G, and a combination of protein A and protein G genes.

[0012] In some embodiments, both ends of the non-transmembrane protein gene are connected to the signal peptide (SP) gene of the second expression protein gene and the transmembrane domain (TMD) gene of the second expression protein gene, respectively.

[0013] In some embodiments, the recombinant expression protein gene includes a signal peptide gene of the expression protein gene, the reporter protein gene, and a transmembrane domain gene of the expression protein gene.

[0014] In some embodiments, the expression protein gene is a baculovirus surface protein gene, and both ends of the reporter protein gene are connected to the signal peptide gene of the baculovirus surface protein gene and the transmembrane domain gene of the baculovirus surface protein gene, respectively.

[0015] In some embodiments, the reporter protein gene is selected from the group consisting of alkaline phosphatase (AP), fluorescent protein (FP), horseradish peroxidase (HRP), luciferase, protein A, protein G, a combination of protein A and protein G, or genes for coloring reaction chemicals.

[0016] In some embodiments, the first promoter and the second promoter are each strong promoters of very late genes.

[0017] According to a second aspect of the present invention, a recombinant baculovirus is provided, comprising: a recombinant baculovirus gene, an envelope, an exogenous protein, and a recombinant expression protein. The recombinant baculovirus gene comprises: a baculovirus gene and a recombinant baculovirus plasmid according to the first aspect of the present invention. The recombinant baculovirus plasmid embeds the baculovirus gene. The envelope encapsulates the recombinant baculovirus gene. The exogenous protein and the recombinant expression protein are both disposed on the envelope. The exogenous protein is selected from the group consisting of an antibody, an antigen, protein A, protein G, and a combination of protein A and protein G. The recombinant expression protein comprises an expression protein and a reporter protein. According to a third aspect of the present invention, a detection kit is provided, comprising: a well plate, an antibody, and the recombinant baculovirus according to the second aspect of the present invention. The well plate comprises a plurality of reaction wells. The antibody is coated on the inner surface of each reaction well and is configured to bind to a target protein (e.g., an antigen) in a biological sample. The exogenous protein disposed on the envelope of the recombinant baculovirus corresponds to a specific protein in the biological sample and is configured to bind to the corresponding specific protein.

[0018] In some embodiments, the exogenous protein is the antibody or the antigen, and the specific protein is the antigen or antibody corresponding to the antibody or the antigen.

[0019] In some embodiments, the exogenous protein is protein A, protein G, or a combination of protein A and protein G, the exogenous protein binds to an antibody, and the specific protein is an antigen corresponding to the antibody.

[0020] In some embodiments, the titer of the recombinant baculovirus is 10 4 to 10 8 Plaque forming unit PFU (Plaque forming unit).

[0021] In some embodiments, the antibody is an anti-human immunoglobulin antibody.

[0022] According to a fourth aspect of the present invention, a microfluidic system is provided, comprising: a microfluidic module. The microfluidic module comprises: a first transmission groove, a sample chamber, a filter chamber, a microfluidic channel, a second transmission groove, a buffer chamber, a sensing chamber, a capture layer and a waste chamber. The sample chamber is connected to the first transmission groove to accommodate the object to be tested. The microfluidic channel connects the sample chamber and the filter chamber and is located between the sample chamber and the filter chamber. The buffer chamber is connected to the second transmission groove to accommodate the buffer liquid. The sensing chamber connects the filter chamber and the buffer chamber and is located between the filter chamber and the buffer chamber. The capture layer is coated on the inner surface of the sensing chamber, and the capture layer includes a recombinant baculovirus. The envelope of the recombinant baculovirus is pierced with exogenous proteins. The waste chamber is connected to the sensing chamber.

[0023] According to a fifth aspect of the present invention, a microfluidic system is provided, comprising: a microfluidic module. The microfluidic module comprises: a first transmission groove, a sample chamber, a filter chamber, a microfluidic channel, a second transmission groove, a buffer chamber, a sensing chamber, a capture layer and a waste chamber. The sample chamber is connected to the first transmission groove to accommodate the object to be tested. The microfluidic channel connects the sample chamber and the filter chamber and is located between the sample chamber and the filter chamber. The buffer chamber is connected to the second transmission groove to accommodate the buffer liquid. The sensing chamber connects the filter chamber and the buffer chamber and is located between the filter chamber and the buffer chamber. The capture layer is coated on the inner surface of the sensing chamber, and the capture layer includes the recombinant baculovirus according to the second aspect of the present invention. The envelope of the recombinant baculovirus is pierced with exogenous proteins. The waste chamber is connected to the sensing chamber.

[0024] In some embodiments, the microfluidic system further comprises: a chipset located at the bottom of the inner surface of the sensing cavity; wherein the exogenous protein is selected from the group consisting of antibodies, antigens, protein A, protein G, and a combination of the protein A and the protein G.

[0025] In some embodiments, the chipset includes: a first biosensing chip and a second biosensing chip, wherein the first biosensing chip is coated with the capture layer, and the second biosensing chip is not coated with the capture layer.

[0026] In some embodiments, the microfluidic module further includes: a third transmission groove; and a probe cavity, connecting the third transmission groove and the sensing cavity, and located between the third transmission groove and the sensing cavity, the probe cavity being used to accommodate a probe; wherein the exogenous protein is selected from a group consisting of antibodies, antigens, protein A, protein G, and a combination of the protein A and the protein G.

[0027] According to a sixth aspect of the present invention, a microfluidic system is provided, comprising: a microfluidic module and a recombinant baculovirus according to the second aspect of the present invention. The microfluidic module comprises: a first transmission groove, a sample chamber, a filter chamber, a microfluidic channel, a second transmission groove, a virus chamber, a reaction chamber, a third transmission groove, a buffer chamber, a sensing chamber, a capture layer, and a waste chamber. The sample chamber is connected to the first transmission groove to accommodate the test substance. The microfluidic channel connects the sample chamber and the filter chamber and is located between the sample chamber and the filter chamber. The virus chamber is connected to the second transmission groove to accommodate the recombinant baculovirus. The reaction chamber is connected to the filter chamber and the virus chamber and is located between the filter chamber and the virus chamber. The buffer chamber is connected to the third transmission groove to accommodate the buffer liquid. The sensing chamber is connected to the reaction chamber and the buffer chamber and is located between the reaction chamber and the buffer chamber. The capture layer is coated on the inner surface of the sensing chamber, and the capture layer includes antibodies. The waste chamber is connected to the sensing chamber.

[0028] According to the seventh aspect of the present invention, a microfluidic system is provided, comprising: a microfluidic module and a recombinant baculovirus according to the second aspect of the present invention. The microfluidic module comprises: a first transmission groove, a sample chamber, a filter chamber, a microfluidic channel, a second transmission groove, a buffer chamber, a third transmission groove, a virus chamber, a sensing chamber, a capture layer and a waste chamber. The sample chamber is connected to the first transmission groove to accommodate the test object. The microfluidic channel connects the sample chamber and the filter chamber and is located between the sample chamber and the filter chamber. The buffer chamber is connected to the second transmission groove to accommodate the buffer liquid. The virus chamber is connected to the third transmission groove to accommodate the recombinant baculovirus. The sensing chamber connects the filter chamber, the buffer chamber and the virus chamber and is located between the filter chamber, the buffer chamber and the virus chamber. The capture layer is coated on the inner surface of the sensing chamber, and the capture layer includes antibodies. The waste chamber is connected to the sensing chamber.

[0029] In summary, the recombinant baculovirus plasmid, recombinant baculovirus, detection kit, or microfluidic system according to any embodiment can reduce the development cost of disease detection and identification, shorten the number of operation steps and operation time, and improve the specificity and signal strength of detection. It can be applied to all applications based on antigen-antibody immune reactions, including disease diagnosis, health examinations, pathogen identification, epidemiological surveys, and scientific research, thereby benefiting social health and scientific development. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] The above and other features, advantages and aspects of the embodiments of the present invention will become more apparent with reference to the following detailed description in conjunction with the accompanying drawings. In the accompanying drawings, the same or similar reference numerals represent the same or similar elements.

[0031] FIG1 is a schematic diagram of a recombinant bacmid according to some embodiments.

[0032] FIG. 2 is a schematic diagram of the recombinant expression protein gene of the recombinant bacmid of FIG. 1 .

[0033] FIG. 3 is a schematic diagram of an exemplary exogenous protein gene in the recombinant bacmid of FIG. 1 .

[0034] FIG. 4 is a schematic diagram of another exemplary embodiment of the foreign protein gene in the recombinant bacmid of FIG. 1 .

[0035] FIG. 5 is a schematic diagram of a recombinant baculovirus comprising the recombinant baculovirus plasmid of FIG. 1 .

[0036] FIG. 6 is a flow chart of the process for producing the recombinant baculovirus of FIG. 5 .

[0037] FIG7 is a schematic diagram of a detection cartridge according to some embodiments.

[0038] FIG8 is an exploded view of a microfluidic system according to some embodiments.

[0039] FIG9 is a schematic diagram of a microfluidic system according to some embodiments.

[0040] FIG10 is a schematic diagram of a microfluidic system according to some other embodiments.

[0041] FIG11 is a schematic diagram of a microfluidic system according to yet other embodiments.

[0042] FIG12 is a schematic diagram of a microfluidic system according to still other embodiments.

[0043] FIG13 is a cross-sectional view of a biosensing chip according to an embodiment.

[0044] FIG14 is a schematic cross-sectional view of a biosensing chip according to another embodiment from one perspective.

[0045] FIG. 15 is a schematic cross-sectional view of a field effect transistor of the biosensor chip of FIG. 13 .

[0046] FIG16 is a schematic cross-sectional view of a biosensor chip and a circuit board according to yet another embodiment.

[0047] FIG17 is a partial enlarged view of the position marked AA in the microfluidic channel system of FIG8.

[0048] FIG18 is a graph showing the electrophoresis test results of the GP64 signal peptide fragment gene, SEAP fragment gene, GP64 transmembrane domain fragment gene, and recombinant expression protein gene.

[0049] FIG19 is a schematic diagram of a bacmid according to some embodiments.

[0050] FIG. 20 is a schematic diagram of the process of incorporating a recombinant expression protein gene into the bacmid of FIG. 19 .

[0051] FIG21 is a graph showing the electrophoresis results of the Colony PCR product of the recombinant bacmid A.

[0052] FIG22 is a graph showing the electrophoresis test results of the prME fragment gene of serotype I dengue virus, the prME fragment gene of serotype II dengue virus, the prME fragment gene of serotype III dengue virus, and the prME fragment gene of serotype IV dengue virus.

[0053] FIG23 is a graph showing the results of electrophoresis test of recombinant bacmid A.

[0054] FIG24 is a graph showing the results of electrophoresis of the Colony PCR product of the recombinant bacmid B1.

[0055] FIG25 is a graph showing the results of electrophoresis of the Colony PCR product of the recombinant bacmid B2.

[0056] FIG26 is a graph showing the results of electrophoresis of the Colony PCR product of the recombinant bacmid B3.

[0057] FIG27 is a graph showing the results of electrophoresis of the Colony PCR product of the recombinant bacmid B4.

[0058] FIG28 is a graph showing the results of electrophoresis test of the prME fragment gene of Japanese encephalitis virus.

[0059] FIG29 is a graph showing the results of electrophoresis of the Colony PCR product of the recombinant bacmid B5.

[0060] FIG30 is a schematic diagram of the process of recombining foreign protein genes into recombinant bacmid A.

[0061] FIG31 is a graph showing the results of a cell fluorescence test.

[0062] FIG32 is a diagram showing the results of a cell fluorescence staining test.

[0063] FIG33 is a histogram showing the results of a SEAP activity test.

[0064] FIG34 is a histogram showing the results of a SEAP activity assay.

[0065] FIG35 is a histogram showing the results of a SEAP activity assay.

[0066] FIG36 is a histogram showing the results of a SEAP activity assay.

[0067] FIG37 is a histogram showing the results of a SEAP activity assay.

[0068] FIG38 is a histogram showing the results of a SEAP activity assay.

[0069] Figure 39 is a schematic diagram of a microfluidic system according to some embodiments.

[0070] FIG. 40 is a schematic diagram of an exemplary capture layer of the microfluidic system of FIG. 39 .

[0071] FIG41 is a schematic diagram showing an example of antibodies captured by the capture layer of the microfluidic system of FIG39.

[0072] FIG. 42 is a schematic diagram of another exemplary capture layer of the microfluidic system of FIG. 39 .

[0073] FIG43 is a schematic diagram showing another exemplary embodiment of antigen capture by the capture layer of the microfluidic system of FIG39.

[0074] FIG. 44 is a schematic diagram of another exemplary capture layer of the microfluidic system of FIG. 39 .

[0075] FIG45 is a schematic diagram showing another exemplary embodiment of the capture layer of the microfluidic system of FIG39 capturing antigens.

[0076] FIG46 is a graph showing electronic signals of the chipset of the microfluidic system of FIG39.

[0077] FIG47 is a schematic diagram of a microfluidic system according to some other embodiments.

[0078] FIG48 is a schematic diagram of an exemplary capture layer of the microfluidic system of FIG47.

[0079] FIG. 49 is a schematic diagram showing an example of an antibody being captured and bound to a probe by the capture layer of the microfluidic system of FIG. 47 .

[0080] FIG50 is a line graph showing the difference in optical signals generated by the first biosensor chip and the second biosensor chip of the microfluidic system of FIG49 and the antibody concentration.

[0081] FIG. 51 is a schematic diagram of another exemplary capture layer of the microfluidic system of FIG. 47 .

[0082] FIG. 52 is a schematic diagram showing another exemplary embodiment of the capture layer of the microfluidic system of FIG. 47 capturing antigens and binding to probes.

[0083] FIG. 53 is a schematic diagram of another exemplary capture layer of the microfluidic system of FIG. 47 .

[0084] FIG. 54 is a schematic diagram showing another exemplary embodiment of the capture layer of the microfluidic system of FIG. 47 capturing antigens and binding to probes.

[0085] FIG55 is a line graph showing the difference in optical signals generated by the first biosensor chip and the second biosensor chip of the microfluidic system of FIG52 or FIG54 and the antigen concentration.

[0086] FIG. 56 is a schematic diagram of a microfluidic system according to yet other embodiments.

[0087] FIG. 57 is a schematic diagram of an exemplary embodiment of the recombinant baculovirus in the microfluidic system of FIG. 56 .

[0088] FIG. 58 is a schematic diagram of an exemplary recombinant baculovirus-bound antibody in the microfluidic system of FIG. 56 .

[0089] FIG. 59 is a schematic diagram showing an example of a recombinant baculovirus in the microfluidic system of FIG. 56 binding to an antibody and binding to a capture layer.

[0090] FIG. 60 is a schematic diagram of another exemplary embodiment of the recombinant baculovirus in the microfluidic system of FIG. 56 .

[0091] FIG. 61 is a schematic diagram showing another exemplary embodiment of recombinant baculovirus binding to antigen in the microfluidic system of FIG. 56 .

[0092] FIG. 62 is a schematic diagram showing another exemplary embodiment of the recombinant baculovirus in the microfluidic system of FIG. 56 binding to an antigen and binding to a capture layer.

[0093] FIG. 63 is a schematic diagram of a microfluidic system according to still other embodiments.

[0094] FIG64 is a schematic diagram of an exemplary capture layer of the microfluidic system of FIG63.

[0095] FIG65 is a schematic diagram showing an example of antigen capture by the capture layer of the microfluidic system of FIG63 .

[0096] FIG. 66 is a schematic diagram showing an example of the capture layer of the microfluidic system of FIG. 63 capturing an antigen and binding it to a recombinant baculovirus.

[0097] FIG. 67 is a schematic diagram of another exemplary capture layer of the microfluidic system of FIG. 63 .

[0098] FIG. 68 is a schematic diagram showing another exemplary embodiment of the capture layer of the microfluidic system of FIG. 63 capturing an antigen.

[0099] FIG. 69 is a schematic diagram showing an example of the capture layer of the microfluidic system of FIG. 63 capturing an antigen and binding it to a recombinant baculovirus. DETAILED DESCRIPTION

[0100] The following describes the present invention and some preferred embodiments thereof to facilitate understanding of the features of the present invention by those skilled in the art. While preferred embodiments of the present invention are shown in the accompanying drawings, it should be understood that the present invention may be implemented in various forms and is not intended to be limited by the embodiments set forth herein. Rather, these embodiments are provided to make the present invention more thorough and complete and to fully convey the scope of the present invention to those skilled in the art.

[0101] As used herein, the term "including" and its variations represent open inclusion, i.e., "including but not limited to." Unless otherwise stated, the term "or" means "and / or." The term "based on" means "based at least in part on." The terms "one example embodiment" and "an embodiment" mean "at least one example embodiment." The term "another embodiment" means "at least one additional embodiment." The terms "first," "second," etc. may refer to different or identical objects.

[0102] Referring to Figure 1 , in some embodiments, a recombinant bacmid 12 includes a bacmid 120, a recombinant expression protein gene 121, and a foreign protein gene 122. The recombinant expression protein gene 121 and the foreign protein gene 122 are located on the bacmid 120. Referring to Figure 2 , the recombinant expression protein gene 121 includes an expression protein gene 1211 and a reporter protein gene 1212.

[0103] In some embodiments, the recombinant bacmid 12 is constructed using restriction enzymes and ligases with the recombinant expression protein gene 121 , the foreign protein gene 122 , and the bacmid 120 as materials.

[0104] Continuing with Figure 1 , in some embodiments, a bacmid 120 includes a right Tn7 transposon (Tn7R), a left Tn7 transposon (Tn7L), a first promoter 123, and a second promoter 124. The first promoter 123 is located between Tn7R and Tn7L. The second promoter 124 is located between the first promoter 123 and Tn7L. The recombinant expression protein gene 121 is located between the second promoter 124 and Tn7L. The exogenous protein gene 122 is located between Tn7R and the first promoter 123.

[0105] In other embodiments, a recombinant bacmid 12 is constructed using the CRISPR / CAS9 system using a recombinant expression protein gene 121, a foreign protein gene 122, and a bacmid 120 as materials. In this embodiment, the recombinant expression protein gene 121 and the foreign protein gene 122 are not restricted to specific locations on the bacmid 120. In other words, the recombinant expression protein gene 121 and the foreign protein gene 122 can be located at any location on the bacmid 120. In some embodiments, the recombinant expression protein gene 121 and / or the foreign protein gene 122 can be located upstream or downstream of the first promoter 123, or upstream or downstream of the second promoter 124. In some embodiments, the bacmid 120 further comprises other promoters, and the recombinant expression protein gene 121 and / or the foreign protein gene 122 can also be located upstream or downstream of the other promoters.

[0106] In some embodiments, the baculovirus plasmid 120 also includes an mCherry gene (not shown) to detect successful cell infection by the recombinant baculovirus. For example, the first promoter 123 is located on one side of the Tn7R, while the mCherry gene is located on the other side of the Tn7R. In other words, the first promoter 123 and the mCherry gene are located on either side of the Tn7R.

[0107] In some embodiments, the exogenous protein gene 122 is a transmembrane protein gene 122A or a non-transmembrane protein recombinant gene 122B.

[0108] Referring to FIG3 , in some embodiments, the exogenous protein gene 122 is a transmembrane protein gene 122A, and the transmembrane protein gene 122A is an antigen gene. Referring also to FIG5 , the transmembrane protein translated from the transmembrane protein gene 122A is expressed on the mantle 13. When the exogenous protein gene 122 is the transmembrane protein gene 122A, the exogenous protein 14 translated from the exogenous protein gene 122 is also expressed on the mantle 13.

[0109] In some embodiments, the antigen gene is a dengue virus antigen gene or a Japanese encephalitis virus antigen gene.

[0110] In some embodiments, the antigen gene is a pre-membrane protein (prM) gene, an envelope protein (E) gene, or a combination thereof.

[0111] 4 , in some embodiments, the exogenous protein gene 122 is a non-transmembrane protein recombinant gene 122B, which includes a non-transmembrane protein gene 1222 and a second expression protein gene 1221 . The non-transmembrane protein gene 1222 is an antibody gene, an antigen gene, a protein A gene, a protein G gene, or a combination of a protein A gene and a protein G gene.

[0112] In some embodiments, the non-transmembrane protein gene 1222 is connected at both ends to a signal peptide (SP) gene 1221A of a second expression protein gene 1221 and a transmembrane domain (TMD) gene 1221B of the second expression protein gene 1221. Referring to FIG5 , the second expression protein translated from the signal peptide gene 1221A and the transmembrane domain gene 1221B of the second expression protein gene 1221 is expressed on the mantle 13, thereby allowing the non-transmembrane protein translated from the non-transmembrane protein gene 1222 to be expressed on the mantle 13. That is, the exogenous protein 14 containing the non-transmembrane protein translated from the exogenous protein gene 122 containing the non-transmembrane protein gene 1222 is expressed on the mantle 13.

[0113] In some embodiments, the second expression protein gene 1221 is a baculovirus surface protein gene. In some embodiments, the second expression protein gene 1221 is a GP64 protein gene. GP64 is a baculovirus transmembrane protein, typically expressed on the baculovirus surface. The GP64 protein translated from the GP64 protein gene can subsequently express the non-transmembrane protein translated from the non-transmembrane protein gene 1222 on the baculovirus surface.

[0114] In some embodiments, the non-transmembrane protein gene 1222 is a protein A gene, a protein G gene, or a combination of protein A and protein G genes. Because protein A and / or protein G bind to the Fc region (fragment crystallizable region) in the antibody structure, the bound antibodies have properties such as consistent orientation and neat arrangement. This can be used to address the disadvantages of antibody function loss caused by inconsistent orientation and irregular arrangement of antibodies when coating antibodies using methods such as immersion in biochip development.

[0115] 2 , in some embodiments, the recombinant expression protein gene 121 includes a signal peptide gene 1211A of the expression protein gene 1211, a reporter gene 1212, and a transmembrane domain gene 1211B of the expression protein gene 1211. The signal peptide gene 1211A, the reporter gene 1212, and the transmembrane domain gene 1211B of the expression protein gene 1211 are sequentially connected.

[0116] In some embodiments, the expression protein gene 1211 is a baculovirus surface protein gene. The two ends of the reporter protein gene 1212 are connected to the signal peptide gene 1211A of the baculovirus surface protein gene and the transmembrane domain gene 1211B of the baculovirus surface protein gene, respectively.

[0117] In some embodiments, the expression protein gene 1211 is the GP64 protein gene. GP64 protein is a baculovirus transmembrane protein typically expressed on the baculovirus surface. The GP64 protein translated from the GP64 protein gene can subsequently express the reporter protein translated from the reporter protein gene 1212 on the baculovirus surface.

[0118] In some embodiments, reporter protein gene 1212 is a non-transmembrane protein gene. In some embodiments, reporter protein gene 1212 is a gene encoding alkaline phosphatase (AP), fluorescent protein (FP), horseradish peroxidase (HRP), luciferase, protein A, protein G, a combination of protein A and protein G, or a coloring agent. The reporter protein translated from reporter protein gene 1212 is expressed on the envelope via expression protein 151 translated from expression protein gene 1211, allowing the recombinant baculovirus to function as a material that emits luminescence, fluorescence, or color.

[0119] In some embodiments, the first promoter 123 and the second promoter 124 are strong promoters of very late genes, in some embodiments, the first promoter 123 is the p10 promoter, and the second promoter 124 is the polH (polyhedrin) promoter.

[0120] Referring to Figure 5 , in some embodiments, a recombinant baculovirus 100 includes a recombinant baculovirus gene 10, an envelope 13, an exogenous protein 14, and a recombinant expression protein 15. The recombinant baculovirus gene 10 includes a baculovirus gene 11 and a recombinant baculovirus plasmid 12. The recombinant baculovirus plasmid 12 is embedded in the baculovirus gene 11. The envelope 13 encapsulates the recombinant baculovirus gene 10. The exogenous protein 14 and the recombinant expression protein 15 are both disposed on the envelope 13. The exogenous protein 14 can be an antibody, an antigen, protein A, protein G, or a combination of proteins A and G. The recombinant expression protein 15 includes an expression protein 151 and a reporter protein 152. The expression protein 151 is a baculovirus surface protein. In some embodiments, the expression protein 151 is GP64 protein. The reporter protein 152 can be alkaline phosphatase, a fluorescent protein, horseradish peroxidase, luciferase, protein A, protein G, a combination of proteins A and G, or a coloring reaction chemical. By amplifying and concentrating recombinant baculovirus 100 that directly displays exogenous protein 14 on its surface, recombinant baculovirus 100 can be used directly as the antigen or antibody required for serum testing, significantly reducing the cost of purification required after antigen or antibody production in expression systems such as E. coli, yeast, or cells. Furthermore, reporter protein 152, displayed on the surface of recombinant baculovirus 100, can be used as the secondary antibody required for serum testing, significantly reducing antibody usage and thus development costs. The simultaneous expression of exogenous protein 14 and recombinant expression protein 15 (including expression protein 151 and reporter protein 152) on the surface of recombinant baculovirus 100 significantly reduces the cost of serum testing reagent development and enhances product competitiveness.

[0121] In some embodiments, the baculovirus is an alphabaculovirus (group I). In some embodiments, the baculovirus is Autographa californica multiple nucleopolyhedrovirus (AcMNPV) or Bombyx morinucleopolyhedrovirus (BmNPV). Preferably, the baculovirus is Autographa californica multiple nucleopolyhedrovirus (AcMNPV).

[0122] Referring to Figure 6 , in some embodiments, the recombinant baculovirus production process comprises the following steps: After the recombinant baculovirus plasmid 12 is generated (step S1), the recombinant baculovirus 100 is generated (step S2). Next, the recombinant baculovirus 100 is used to infect cells (step S3), and the recombinant baculovirus 100 is amplified using the cells (step S4). The recombinant baculovirus particles are then purified (step S5), and the recombinant baculovirus 100 can be used for subsequent applications (step S6). In some embodiments, the recombinant baculovirus 100 can be used in assays, such as assay cartridges or microfluidic systems containing the recombinant baculovirus 100.

[0123] In some embodiments, referring to FIG. 7 and FIG. 5 , a detection kit 200 is shown, which is suitable for detecting the content of a specific protein 23 in a biological sample. Here, the detection kit 200 includes: a well plate 20, an antibody 21, and a recombinant baculovirus 100. The well plate 20 includes a plurality of reaction wells 201. In some embodiments, referring to a reaction well 201, the antibody 21 can be coated on the inner surface of the reaction well 201 for binding to a target protein 22 in the biological sample. The exogenous protein 14 expressed on the surface of the recombinant baculovirus 100 corresponds to a specific protein 23 in the target protein 22 in the biological sample and is used to bind to the corresponding specific protein 23. By detecting the expression level of the reporter protein 152 expressed on the surface of the recombinant baculovirus 100, the content of the specific protein 23 in the biological sample can be obtained. By using a recombinant baculovirus 100 that simultaneously expresses an exogenous protein 14 and a recombinant expression protein 15 (including an expression protein 151 and a reporter protein 152) on its surface, the detection kit has a more time-saving detection process, simpler operation steps, and lower detection costs. In addition, compared with other existing detection kits that do not use secondary antibodies, it has higher specificity and stronger signals.

[0124] In some embodiments, when the exogenous protein 14 is an antibody, the specific protein 23 is an antigen corresponding to the antibody. For example, when the exogenous protein 14 is a dengue virus antibody, the specific protein 23 is a dengue virus antigen corresponding to the dengue virus antibody. In some embodiments, when the exogenous protein 14 is an antigen, the specific protein 23 is an antibody corresponding to the antigen. For example, when the exogenous protein 14 is a dengue virus antigen, the specific protein 23 is a dengue virus antibody corresponding to the dengue virus antigen.

[0125] In some embodiments, when the exogenous protein 14 is protein A, protein G, or a combination of protein A and protein G, protein A and / or protein G bind to an antibody, and the specific protein 23 is an antigen corresponding to the antibody. For example, when the exogenous protein 14 is protein A, protein G, or a combination of protein A and protein G, protein A and / or protein G bind to a dengue virus antibody, and the specific protein 23 is a dengue virus antigen corresponding to the dengue virus antibody.

[0126] In some embodiments, compared to a detection kit that requires the use of a secondary antibody, the detection kit 200 comprising the recombinant baculovirus 100 can reduce the step of using the secondary antibody, saving approximately one hour or more of time, and can also reduce the cost of purchasing the secondary antibody.

[0127] In some embodiments, the titer of the recombinant baculovirus 100 is 10 4 to 10 8 PFU (Plaque forming unit). Preferably, the titer of the recombinant baculovirus 100 is 10 4 to 10 6 More preferably, the titer of the recombinant baculovirus 100 is 10 6 PFU.

[0128] In some embodiments, antibody 21 is an anti-human immunoglobulin antibody. In some embodiments, antibody 21 is an anti-IgG and / or anti-IgM antibody.

[0129] Referring to Figures 8 and 9, in some embodiments, a microfluidic system M1 includes a microfluidic module 300. The microfluidic module 300 comprises a first transfer trough 31A, a sample chamber 32, a filtration chamber 33, a microfluidic channel 34, a second transfer trough 31B, a buffer chamber 35A, a sensing chamber 36, a capture layer 361, and a waste chamber 37. The sample chamber 32 is connected to the first transfer trough 31A and is used to hold an analyte, which may be a liquid biomolecule containing a specific biomolecule that is a detection target. The microfluidic channel 34 connects the sample chamber 32 and the filtration chamber 33 and is located between them. The buffer chamber 35A is connected to the second transfer trough 31B and is used to hold a buffer liquid. The sensing chamber 36 is connected to the filtration chamber 33 and the buffer chamber 35A and is located between them. The capture layer 361 is coated on the inner surface of the sensing chamber 36 and comprises a recombinant baculovirus. The envelope of the recombinant baculovirus is pierced with exogenous proteins. The waste chamber 37 is connected to the sensing chamber 36.

[0130] In some embodiments, the sample chamber 32 further has a sample inlet 321 for receiving the analyte.

[0131] In some embodiments, the exogenous protein is an antibody, an antigen, protein A, protein G, or a combination of protein A and protein G.

[0132] In some embodiments, the microfluidic system M1 further includes a buffer solution contained in the buffer chamber 35A.

[0133] Referring to Figure 10 , in some embodiments, the microfluidic module 300 further includes a third transmission slot 31C and a probe cavity 38. The probe cavity 38 connects the third transmission slot 31C and the sensing cavity 36 and is located between the third transmission slot 31C and the sensing cavity 36. The probe cavity 38 is used to accommodate a probe. In some embodiments, the microfluidic system M1 further includes a probe accommodated in the probe cavity 38.

[0134] In some embodiments, the probe is a secondary antibody or other protein with a reporter protein. In some embodiments, the reporter protein can be a fluorescent protein, alkaline phosphatase, or horseradish peroxidase.

[0135] In some embodiments, the microfluidic module 300 further includes a fourth transmission slot 31D and a second buffer chamber 35B. The second buffer chamber 35B connects the fourth transmission slot 31D and the sensing chamber 36 to accommodate a second buffer liquid. In some embodiments, the microfluidic system M1 further includes a second buffer liquid accommodated in the second buffer chamber 35B.

[0136] In some embodiments, the fourth transmission groove 31D and the second transmission groove 31B can be the same transmission groove. In some embodiments, the second buffer cavity 35B and the buffer cavity 35A can be the same buffer cavity.

[0137] Referring to Figure 11 , in some embodiments, a microfluidic system M2 includes a microfluidic module 400 and a recombinant baculovirus 100. The microfluidic module 400 comprises a first transfer slot 41A, a sample chamber 42, a filtration chamber 43, a microfluidic channel 44, a second transfer slot 41B, a virus chamber 48, a reaction chamber 49, a third transfer slot 41C, a buffer chamber 45, a sensing chamber 46, a capture layer 461, and a waste chamber 47. The sample chamber 42 is connected to the first transfer slot 41A and is used to hold an analyte. The microfluidic channel 44 connects the sample chamber 42 and the filtration chamber 43 and is located between them. The virus chamber 48 is connected to the second transfer slot 41B and is used to hold the recombinant baculovirus 100. The reaction chamber 49 connects the filtration chamber 43 and the virus chamber 48 and is located between them. The buffer chamber 45 is connected to the third transfer slot 41C and is used to hold a buffer liquid. Sensing chamber 46 connects to reaction chamber 49 and buffer chamber 45, and is located between them. Capture layer 461, comprising antibodies, is coated on the inner surface of sensing chamber 46. Waste chamber 47 connects to sensing chamber 46. The envelope of recombinant baculovirus 100 is perforated with exogenous proteins and reporter proteins.

[0138] Referring to Figure 12 , in some embodiments, a microfluidic system M3 includes a microfluidic module 500 and a recombinant baculovirus 100. The microfluidic module 500 includes a first transfer slot 51A, a sample chamber 52, a filtration chamber 53, a microfluidic channel 54, a second transfer slot 51B, a buffer chamber 55A, a third transfer slot 51C, a virus chamber 58, a sensing chamber 56, a capture layer 561, and a waste chamber 57. The sample chamber 52 is connected to the first transfer slot 51A and is used to hold an analyte. The microfluidic channel 54 connects the sample chamber 52 and the filtration chamber 53 and is located between them. The buffer chamber 55A is connected to the second transfer slot 51B and is used to hold a buffer liquid. The virus chamber 58 is connected to the third transfer slot 51C and is used to hold the recombinant baculovirus 100. The sensing chamber 56 is connected to the filtration chamber 53, the buffer chamber 55A, and the virus chamber 58 and is located between them. The capture layer 561 is coated on the inner surface of the sensing cavity 56 and includes antibodies. The waste cavity 57 is connected to the sensing cavity 56. The envelope of the recombinant baculovirus 100 is pierced with foreign proteins and reporter proteins.

[0139] In some embodiments, the microfluidic module 500 further includes a fourth transmission slot 51D and a second buffer chamber 55B. The second buffer chamber 55B connects the fourth transmission slot 51D and the sensing chamber 56 to accommodate a second buffer liquid. In some embodiments, the microfluidic system M3 further includes a second buffer liquid accommodated in the second buffer chamber 55B.

[0140] In some embodiments, the fourth transmission groove 51D and the second transmission groove 51B can be the same transmission groove. In some embodiments, the second buffer cavity 55B and the buffer cavity 55A can be the same buffer cavity.

[0141] In some embodiments, the first transmission slots 31A, 41A, 51A, the second transmission slots 31B, 41B, 51B, the third transmission slots 31C, 41C, 51C, and the fourth transmission slots 31D, 51D are used to accommodate actuators. When the actuators generate pressure, the analytes are moved from the sample chambers 32, 42, 52 to the microchannels 34, 44, 54. For example, if the actuators are air pumps, when the airflow generated by the air pumps flows into the sample chambers 32, 42, 52, the airflow exerts pressure on the analytes in the sample chambers 32, 42, 52, pushing the analytes into the microchannels 34, 44, 54 and then into the filter chambers 33, 43, 53.

[0142] In some embodiments, microfluidic systems M1, M2, and M3 further include a chipset 362, 462, or 562. Chipset 362, 462, or 562 is located at the bottom of the inner surface of sensing cavity 36, 46, or 56. Referring to FIG8 , in some embodiments, regarding microfluidic system M1, chipset 362 includes a first biosensor chip BC1 and a second biosensor chip BC2. The first biosensor chip BC1 is coated with a capture layer 361, while the second biosensor chip BC2 is not coated with a capture layer 361.

[0143] In some embodiments, the first bio-sensing chip BC1 and the second bio-sensing chip BC2 are implemented using extended-gate field-effect transistors (EGFETs).

[0144] Referring to Figures 13 and 14 , in some embodiments, the first biosensor chip BC1 and the second biosensor chip BC2 are biosensor chips 60, comprising a field-effect transistor 600, an insulating layer 620, a conductive layer 630, and a sensing layer 650. Field-effect transistor 600 has a gate 602. Insulating layer 620 is disposed on field-effect transistor 600 and covers gate 602. Conductive layer 630 is disposed within insulating layer 620 and electrically connected to gate 602 via conductive pillars 640. Sensing layer 650 is disposed on insulating layer 620 and electrically connected to conductive layer 630 via conductive pillars 640. Sensing layer 650 has a sensing surface 652, which is the surface of sensing layer 650 opposite conductive pillars 640. Sensing surface 652 includes a plurality of nanoparticles 654.

[0145] In some embodiments, the sensing layer 650 functions as an extended gate and is electrically connected to the gate 602 of the field-effect transistor 600, thereby forming an extended-gate field-effect transistor (EGFET) in the biosensor chip 60. The conductive layer 630 and the conductive pillars 640 function as conductors connecting the gate 602 and the sensing layer 650 in the EGFET.

[0146] In some embodiments, the insulating layer 620 includes a first insulating layer 622 and a second insulating layer 624. The first insulating layer 622 is formed above the field-effect transistor 600 and covers the gate 602 of the field-effect transistor 600 exposed from the transistor substrate 608. The conductive layer 630 is disposed on the first insulating layer 622. In some embodiments, the conductive layer 630 is located at a position corresponding to the gate 602 of the field-effect transistor 600. In some embodiments, when disposing the conductive layer 630, a conductive pillar 640 can be first formed in the first insulating layer 622 at a position corresponding to the gate 602, and then the conductive layer 630 is disposed at the position corresponding to the conductive pillar 640. In this way, one end of the conductive pillar 640 is connected to the gate 602, and the other end is connected to the conductive layer 630, thereby electrically connecting the gate 602 and the conductive layer 630. In some embodiments, the second insulating layer 624 is formed above the first insulating layer 622 and covers the conductive layer 630 . The sensing layer 650 is disposed above the second insulating layer 624 , and the conductive pillars 640 electrically connect the conductive layer 630 and the sensing layer 650 .

[0147] In some embodiments, the biosensor chip 60 is used to detect or analyze biomolecules. Therefore, the extended gate field-effect transistor structure described above can prevent direct contact between the field-effect transistor 600 in the biosensor chip 60 and the biomolecules to be detected (e.g., biomolecules in liquid form). It can also reduce the impact of light on the field-effect transistor 600, thereby obtaining more accurate detection results.

[0148] Furthermore, the aforementioned structure in which the conductive layer 630 is disposed on the field-effect transistor 600 and the sensing layer 650 is disposed on the conductive layer 630 allows the biosensor chip 60 to form a three-dimensional sensing structure. When multi-channel detection of multiple biomolecules is required, a three-dimensional sensing structure, compared to a two-dimensional sensing structure, allows more biosensor chips 60 to be placed within a limited space (e.g., on the same wafer), thereby increasing the sensing area and improving the signal-to-noise ratio (SNR) during biomolecule detection.

[0149] 15 , the type of field-effect transistor 600 is not limited. In some embodiments, it can be implemented as an N-channel MOSFET, that is, the field-effect transistor 600 is disposed in a P-type transistor substrate 608 with an N-type semiconductor region as the source 604 and drain 606, and the gate 602 is exposed outside the transistor substrate 608. In some embodiments, it can be implemented as a P-channel MOSFET, that is, the field-effect transistor 600 is disposed in an N-type transistor substrate 608 with a P-type semiconductor region as the source 604 and drain 606, and the gate 602 is exposed outside the transistor substrate 608.

[0150] As previously described, the biosensor chip 60 can be used for the detection and analysis of biomolecules. In some embodiments, the sensing surface 652 is the interface with the biomolecules. When biomolecules come into contact with the sensing surface 652, they cause a charge change on the sensing surface 652. Field-effect transistor 600, electrically connected to the sensing layer 650 via the conductive layer 630, captures and analyzes this surface charge change to obtain biomolecule information.

[0151] In some embodiments, the sensing surface 652 comprises a plurality of nanoparticles 654, which can be formed on the sensing surface 652 in various manners. In some embodiments, the nanoparticles 654 are semicircular, convex at the top and flat at the bottom, with a diameter ranging from 50 nanometers to 200 nanometers. This creates a three-dimensional, uneven surface on the sensing surface 652, thereby increasing the surface area of ​​the sensing surface 652 and its sensitivity to surface charge changes. In other embodiments, the nanoparticles 654 are conical, cylindrical, square, rectangular, or any polygonal shape.

[0152] In some embodiments, the nanoparticles 654 can be formed on the sensing surface 652 in a variety of ways. The following are only individual examples and are not intended to limit the formation methods.

[0153] In some embodiments, a plurality of metal droplets may be sprayed or transferred onto the sensing surface 652 by inkjet printing or imprinting. After the metal droplets on the sensing surface 652 dry and solidify, the nanoparticles 654 may be formed.

[0154] In other embodiments, the nanoparticles 654 are deposited using photoresist and electroplating. Specifically, a plurality of photoresists are first deposited on the sensing surface 652. The shape and size of the areas on the sensing surface 652 not blocked by the photoresists correspond to the shape and size of the desired nanoparticles 654. A metal layer is then deposited on the sensing surface 652 not covered by the photoresists using electroplating. The thickness of the metal layer corresponds to the radius of the desired nanoparticles 654. After deposition is complete, the photoresists are removed, and the sensing layer 650 is heated and cooled using rapid thermal annealing to form the nanoparticles 654 on the sensing surface 652.

[0155] In some other embodiments, the nanoparticles 654 are implemented as solid metal particles, and these metal particles can be fixed on the sensing surface 652 by chemical bonding, thereby making the sensing surface 652 form a three-dimensional uneven surface.

[0156] In some embodiments, the metal droplets, metal layer, and metal particles forming the nanoparticles 654 can be made of any metal. The material of the nanoparticles 654 can be selected based on the materials used to make the conductive layer 630 and the sensing layer 650, thereby enhancing the sensing accuracy and sensitivity of the biosensor chip 60. For example, if the conductive layer 630 and the sensing layer 650 are made of gold (Au), the nanoparticles can be made of gold or silver (Ag). If the conductive layer 630 and the sensing layer 650 are made of platinum (Pt), the nanoparticles can be made of platinum or silver.

[0157] In some embodiments, the capture layer 361 is disposed on the biosensor chip 60 , and is disposed on the sensing surface 652 (hereinafter referred to as the three-dimensional surface) of the sensing layer 650 , which is an uneven surface formed of three-dimensional undulations by nanoparticles 654 .

[0158] When the biomolecules to be detected come into contact with the capture layer 361 , the capture layer 361 can bind to the specific biomolecules serving as the detection target, thereby enabling the three-dimensional surface to be used for the detection and analysis of the specific biomolecules.

[0159] Specifically, when multiple biomolecules contact the three-dimensional surface, the capture layer 361 can accurately identify specific target molecules and selectively bind to specific biomolecules to reduce interference from non-target biomolecules and improve detection sensitivity.

[0160] In some embodiments, when the capture layer 361 is disposed on a three-dimensional surface, the capture layer 361 and the sensing surface 652 can be firmly attached to the sensing surface 652 by using isolation methods, encapsulation methods, adsorption methods, covalent bonding methods, etc., wherein the adsorption method can be to fix the capture layer 361 on the three-dimensional surface by physical bonding (such as ionic bonding, hydrophilicity or van der Waals force) or chemical bonding.

[0161] When the capture layer 361 is applied to a three-dimensional surface, visible light can be irradiated onto the sensing surface 652 to confirm whether the capture layer 361 is evenly applied. This is because visible light irradiating the sensing surface 652 generates localized surface plasmon resonance (SPR). If the capture layer 361 is not evenly applied, areas with more and less coating will reflect different colors of light. This resonance phenomenon is particularly pronounced on the gold sensing layer 650 and nanoparticles 654.

[0162] 16 , in some embodiments, the first bio-sensing chip BC1 and the second bio-sensing chip BC2 are bio-sensing chips 70 , which are located on an external circuit 770 . The external circuit 770 can be replaced by a field-effect transistor 772 and electrically connected to the field-effect transistor 772 or the external circuit 770 via a signal connection line 760 in the bio-sensing chip 70 .

[0163] In some embodiments, the biosensor chip 70 includes a substrate 710, an adhesive layer 720, a sensing layer 750, and a signal connection line 760. The adhesive layer 720 and the sensing layer 750 are disposed on the substrate 710. The sensing layer 750 can be disposed above or within the adhesive layer 720, with the adhesive layer 720 merely separating the sensing layer 750 from the substrate 710. The sensing layer 750 includes a plurality of sensing electrodes 752, each including a first sensing electrode 752a and a second sensing electrode 752b. When connected to a field-effect transistor 772, the signal connection line 760 has one end electrically connected to the upper surface of the sensing electrode 752 of the sensing layer 750 and the other end connected to the field-effect transistor 772 or an external circuit 770.

[0164] In some embodiments, the substrate 710 is made of silicon, glass, a flexible substrate, or a combination of these materials. The flexible substrate can be a copper foil laminate (FCCL) made by bonding copper foil and a thin film material. A protective film, a reinforcing plate, an antistatic layer, and other materials can be added to create a reliably bendable flexible substrate.

[0165] In some embodiments, the adhesion layer 720 can be replaced by an oxide layer made of oxide or the insulating layer 620 as described above. The manufacturing material of the adhesion layer 720 can be a material with a low dielectric constant such as silicon oxide, silicon nitride, polyimide (PI), chromium or a polymer of the above materials, and the adhesion layer 720 can be formed on the substrate 710 by chemical oxidation treatment, thermal oxidation treatment, chemical vapor deposition or physical vapor deposition.

[0166] In some embodiments, the capture layer 361 is coated on the sensing layer 750 , and the biosensing chip 70 is used to detect biomolecules.

[0167] In some embodiments, when the sensing layer 750 of the biosensing chip 70 is electrically connected to the gate of the field-effect transistor 772, it forms an extended-gate field-effect transistor (EDFET). In other words, the sensing layer 750 of the biosensing chip 70 can be considered the extended gate of the EGT. Similar to the biosensing chip 60, the EGT structure prevents direct contact between the field-effect transistor 772 in the biosensing chip 70 and the biomolecules being detected, resulting in more accurate detection results.

[0168] In some embodiments, the sensing electrode 752 includes a first sensing electrode 752a and a second sensing electrode 752b. The number of first sensing electrodes 752a and second sensing electrodes 752b is not limited. A field-effect transistor 772 is electrically connected to the first sensing electrode 752a, and the capture layer 361 is disposed on the second sensing electrode 752b. In this case, the biosensor chip 70 may include a conductive layer 730, which may be deposited on the adhesion layer 720 by vacuum evaporation, electroplating, chemical vapor deposition, or physical vapor deposition. The conductive layer 730 includes a plurality of conductive pathways 732, which electrically connect the second sensing electrode 752b (for coating the capture layer 361) with the first sensing electrode 752a (for connecting to the field-effect transistor 772). The electrical connection between the conductive pathways 732 and each of the first sensing electrodes 752a and the second sensing electrodes 752b is achieved through conductive pillars 740.

[0169] In some embodiments, the conductive layer 730 and the sensing layer 750 can be made of aluminum copper, aluminum silicon copper, titanium gold, titanium nitride, or gold. The cross-section of the sensing electrode 752 can be circular, rectangular, or any polygonal shape. The cross-sectional area of ​​the first sensing electrode 752a can be larger than the cross-sectional area of ​​the second sensing electrode 752b, thereby making the connection between the signal connection line 760 and the first sensing electrode 752a more reliable. In other embodiments, the cross-sectional area of ​​the first sensing electrode 752a can be smaller than or equal to the cross-sectional area of ​​the second sensing electrode 752b. The distance between each sensing electrode 752 can be between 30 and 150 microns. The arrangement of the sensing electrodes 752 can be designed based on the type and / or number of capture layers to be placed on the sensing electrodes 752, and is not limited here.

[0170] In some embodiments, the adhesion layer 720 covers the sensing layer 750 . In order to allow the capture layer 361 to contact the sensing layer 750 , the adhesion layer 720 above the sensing layer 750 forms a sensing groove 728 corresponding to the sensing electrode 752 , so that the sensing electrode 752 can be exposed on the adhesion layer 720 .

[0171] In some embodiments, the adhesive layer 720 includes a first adhesive layer 722, a second adhesive layer 724, and a third adhesive layer 726. The first adhesive layer 722 is disposed on the substrate 710 to isolate the sensing layer 750 and the conductive layer 730 from the substrate 710, thereby preventing telecommunication interference between the substrate 710 and the sensing layer 750 and the conductive layer 730. Furthermore, the first adhesive layer 722 ensures that the sensing layer 750 and the conductive layer 730 are firmly attached to the substrate 710.

[0172] The second adhesive layer 724 and the conductive layer 730 are disposed on the first adhesive layer 722, with the second adhesive layer 724 covering the conductive layer 730. The sensing layer 750 is disposed on the second adhesive layer 724. Conductive pillars 740 are provided in the second adhesive layer 724. These pillars electrically connect the sensing layer 730 to the sensing layer 750. One end of each conductive pillar 740 is connected to a first sensing electrode 752a or a second sensing electrode 752b, and the other end is connected to a conductive path 732. As previously described, the conductive layer 730 has a plurality of conductive paths 732, and the sensing layer 750 has a plurality of sensing electrodes 752. Therefore, the second adhesive layer 724 can include a plurality of conductive pillars 740, allowing each sensing electrode 752 to be electrically connected to a conductive path 732 via a conductive pillar 740.

[0173] The third adhesive layer 726 is disposed on the second adhesive layer 724 . The third adhesive layer 726 covers the sensing layer 750 and forms sensing grooves 728 at locations 752 corresponding to the sensing electrodes.

[0174] In some embodiments, the biosensor chip 70 includes a housing 790 that encapsulates the exposed bottom, sides, and top of the substrate 710 and adhesive layer 720. The housing 790 protects the biosensor chip 70. When placed on an external circuit 770, the housing 790 separates the biosensor chip 70 from the external circuit 770, ensuring that only the signal connection lines 760 are electrically connected to the external circuit 770.

[0175] If the housing 790 does not expose the first sensing electrode 752a, the signal connection line 760 must pass through the housing 790 to connect to the external circuit 770 or the field-effect transistor 772. In some embodiments, one end of the signal connection line 760 passes through the housing 790 at the location corresponding to the first sensing electrode 752a and is electrically connected to the first sensing electrode 752a at the sensing slot 728. The other end of the signal connection line 760 remains outside the biosensor chip 70 and can be connected to the external circuit 770 or the gate of the field-effect transistor 772 as needed.

[0176] In other embodiments, one end of the signal connection line 760 passes through the housing 790, the substrate 710, and the first adhesive layer 722 in sequence from the bottom of the housing 790 to connect to the conductive path 732 of the conductive layer 730. The conductive path 732 is electrically connected to the first sensing electrode 752a through the conductive pillar 740. The other end of the signal connection line 760 remains outside the biosensor chip 70 and can be further connected to the external circuit 770 or the field-effect transistor 772.

[0177] In some other embodiments, the end of the signal connection line 760 electrically connected to the conductive path 732 may also pass through the housing 790 and the first adhesive layer 722 from the side of the housing 790 to achieve the effect of electrically connecting to the first sensing electrode 752a.

[0178] In some embodiments, the external circuit 770 or the field effect transistor 772 can be removed and replaced at any time as needed after being connected to the signal connection line 760. The signal connection line 760 can be a component with telecommunication connection and transmission functions such as a wire, a connector, or a plug.

[0179] When manufacturing the biosensor chip 70 , the sensing layer 750 is disposed on the first adhesive layer 722 , and the sensing layer 750 is directly connected via the signal connection line 760 .

[0180] In some embodiments, when the capture layer 361 is disposed on the biosensor chip 70, uneven distribution of the constituent materials of the capture layer 361 may occur. This can cause a significant difference in the potential signal measured by the unevenly distributed sensing electrode 752b compared to other sensing electrodes 752b, leading to errors in the measurement of biomolecules. However, the aforementioned method of electrically connecting the second sensing electrode group 751b to one of the first sensing electrodes 752a can reduce the impact of the uneven distribution of the sensing electrode 752b by averaging the potential signals measured on each second sensing electrode 752b when an uneven distribution problem is detected in one of the second sensing electrodes 752b in the second sensing electrode group 751b.

[0181] In some embodiments, the biosensor chip 70 further includes a reference electrode 780 electrically connected to one of the second sensing electrodes 752b. The reference electrode 780 can be disposed in the sensing groove 728, with the upper surface of the reference electrode 780 being higher than the upper surface of the third adhesive layer 726. When the second sensing electrode 752b senses the charge of the biomolecules it contacts, the reference electrode 780 provides a known and stable potential as a reference for comparison, thereby achieving more accurate sensing. In some embodiments, the reference electrode 780 can be made of silver chloride, silver, or platinum.

[0182] In some embodiments, the biosensor chips 60 and 70 can be used to detect different biomolecules to obtain biomolecule information, such as the pH value of the biomolecule. The biomolecules may be urea, creatine, penicillin, formaldehyde, immune substances, etc.

[0183] Please refer to Figure 17, which is a partial enlarged view of the position marked AA in the microfluidic system M1 of Figure 8. In some embodiments, the inner wall 341 of the microfluidic channel 34 has an antibody coating 342. The antibodies in the antibody coating 342 can bind to certain biomolecules in the analyte, causing some of the biomolecules to aggregate and settle. For example, if the antibody coating 342 is an anti-D antibody and the analyte is blood, after the blood is pushed into the microfluidic channel 34, the anti-D on the inner wall 341 of the microfluidic channel 34 will interact with specific antigens on the surface of Rh(D)-positive red blood cells in the blood, causing the Rh(D)-positive red blood cells to gradually aggregate and settle on the inner wall 341 as the blood flows through the microfluidic channel 34. As a result, the blood flowing from the microfluidic channel 34 to the filtration chamber 33 no longer contains Rh(D)-positive red blood cells.

[0184] In some embodiments, the filter chamber 33 can further filter the analyte flowing from the microchannel 34 to remove more non-target biomolecules. For example, if the analyte is blood, the filter chamber 33 can be equipped with a porous filter membrane. After separating Rh(D)-positive red blood cells, the blood or plasma flowing into the filter chamber 33 is filtered again through the porous filter membrane to remove residual red blood cells (e.g., Rh(D)-negative red blood cells that cannot interact with Anti-D) or debris, leaving only the plasma or serum to flow into the sensing chamber 36.

[0185] Example 1: Construction of recombinant baculovirus plasmid

[0186] 1. Construction of recombinant protein expression gene 121 and recombinant bacmid A

[0187] A PCR instrument (Applied Biosystems 2720 Thermal Cycler, purchased from Applied Biosystems) was used to generate the DNA polymerase ( AcMNPV bacmid (isolated from DH10Bac Competent Cells, purchased from Thermo Fisher Scientific, product number 10361012) was subjected to polymerase chain reaction (PCR) using High-Fidelity DNA Polymerase (purchased from New England Biolabs, product number F-530L) and primers GP64-SP F and GP64-SP-SEAP R in Table 1 to amplify the GP64 signal peptide (GP64-SP) fragment gene 1211A (101 bp); pIB-dsRed-RhiR-SEAP / EGFP (a plasmid constructed in the laboratory, including the SEAP fragment gene 1212a) was subjected to PCR using DNA polymerase and primers SEAP-GP64-SP F and SEAP-GP64-TMD R in Table 1 to amplify the SEAP fragment gene 1212a (1472 bp); and DNA polymerase and primers GP64-TMD-SEAP R in Table 1 were used to amplify the SEAP fragment gene 1212a. AcMNPV bacmid (isolated from DH10Bac Competent Cells, purchased from Thermo Fisher Scientific, product number 10361012) was used for PCR to amplify the GP64 transmembrane domain (GP64-TMD) fragment gene 1211B (124 bp). As shown in FIG18 , the fragments are 101 bp of the GP64 signal peptide fragment gene 1211A (SEQ ID NO: 9), 1472 bp of the SEAP fragment gene 1212a (SEQ ID NO: 10), and 124 bp of the GP64 transmembrane domain fragment gene 1211B (SEQ ID NO: 11).

[0188] Next, an overlapping polymerase chain reaction (PCR) was performed using a PCR instrument with DNA polymerase and the primers GP64-SP F and GP64-TMD R listed in Table 1 to fuse the amplified GP64 signal peptide fragment gene 1211A, SEAP fragment gene 1212a, and GP64 transmembrane domain fragment gene 1211B. These fragments were fused to produce a recombinant expression protein gene 121 (1656 bp). The recombinant expression protein gene 121 includes the GP64 signal peptide fragment gene 1211A, the SEAP fragment gene 1212a, and the GP64 transmembrane domain fragment gene 1211B. These fragments are included in the recombinant expression protein gene 121 in the order of GP64 signal peptide fragment gene 1211A, SEAP fragment gene 1212a, and GP64 transmembrane domain fragment gene 1211B. As shown in FIG18 , it is a 1656 bp recombinant expression protein gene 121 (SEQ ID NO: 12).

[0189] As shown in FIG19 , the bacmid 120 (pFastBac TM The Dual Expression Vector (available from Gibco, product number 10712024) includes two promoters, the mCherry gene, two multiple restriction enzyme cleavage sites (MCS), the right Tn7 transposon (Tn7R), and the left Tn7 transposon (Tn7L). The two promoters are the p10 promoter (Pp10) and the Polyhedrin (polH) promoter (PpolH). The p10 promoter is located between the right and left Tn7 transposon, and the polH promoter is located between the p10 promoter and the left Tn7 transposon. One MCS is located between the p10 promoter and the right Tn7 transposon, and the other MCS is located between the polH promoter and the left Tn7 transposon. The mCherry gene is not shown in the diagram.

[0190] Next, the recombinant expression protein gene 121 was cut with the EcoRI restriction enzyme. The MCS located between the polH promoter and the left Tn7 transposon in the bacmid 120 was also cut with the EcoRI restriction enzyme. The recombinant expression protein gene 121 and the bacmid 120 were then ligated using a ligase, such that the recombinant expression protein gene 121 was ligated downstream of the polH promoter in the bacmid 120, between the polH promoter and the left Tn7 transposon, to produce recombinant bacmid A. FIG20 is a schematic diagram of the recombinant bacmid A. Furthermore, colony polymerase chain reaction (PCR) was performed on the recombinant bacmid A using a PCR instrument to confirm that the recombinant bacmid A contained the recombinant expression protein gene 121, which contained the GP64 signal peptide fragment gene 1211A, SEAP fragment gene 1212a, and GP64 transmembrane domain fragment gene 1211B linked in sequence. The recombinant bacmid A was then sent for sequencing. As shown in FIG. 21 , the colony PCR products of recombinant bacmids A, No. 1, No. 2, and No. 3, are 1381 bp in length, confirming that the construction of recombinant bacmid A includes the recombinant expression protein gene 121 of the GP64 signal peptide fragment gene 1211A, the SEAP fragment gene 1212a, and the GP64 transmembrane domain fragment gene 1211B linked in sequence.

[0191] Table 1

[0192] 2. Construction of Recombinant Baculovirus Plasmid B

[0193] The foreign protein gene 122 may be an antigen gene, such as a dengue virus prME (pre-membrane protein (prM) and envelope protein (E)) fragment gene or a Japanese encephalitis virus prME fragment gene.

[0194] Dengue virus prME segment genes include the precursor membrane protein segment gene and the envelope protein segment gene. The dengue virus prME segment genes (sequences synthesized in the laboratory) include the serotype I dengue virus prME segment gene 122A1 (SEQ ID NO: 13), the serotype II dengue virus prME segment gene 122A2 (SEQ ID NO: 14), the serotype III dengue virus prME segment gene 122A3 (SEQ ID NO: 15), and the serotype IV dengue virus prME segment gene 122A4 (SEQ ID NO: 16). Sequences of the serotype I dengue virus prME segment gene 122A1, serotype II dengue virus prME segment gene 122A2, serotype III dengue virus prME segment gene 122A3, and serotype IV dengue virus prME segment gene 122A4 were cleaved with SalI and SpeI restriction enzymes, respectively, to confirm sequence accuracy (as shown in Figure 22).

[0195] Furthermore, the recombinant bacmid A was cut with XhoI and NheI restriction enzymes (7643 bp and 1272 bp after cutting) to confirm the sequence accuracy (as shown in FIG. 23 ). Next, the serotype I dengue virus prME fragment gene 122A1, serotype II dengue virus prME fragment gene 122A2, serotype III dengue virus prME fragment gene 122A3, and serotype IV dengue virus prME fragment gene 122A4 were ligated to the recombinant bacmid A using a ligase, such that the serotype I dengue virus prME fragment gene 122A1, serotype II dengue virus prME fragment gene 122A2, serotype III dengue virus prME fragment gene 122A3, and serotype IV dengue virus prME fragment gene 122A4 were ligated downstream of the p10 promoter of the recombinant bacmid A, between the p10 promoter and the right Tn7 transposon, to produce recombinant bacmid B1 (SEQ ID NO: 18), recombinant bacmid B2 (SEQ ID NO: 19), and recombinant bacmid B3 (SEQ ID NO: 20). NO:20), and recombinant bacmid B4 (SEQ ID NO:21).

[0196] Furthermore, colony PCR was performed on recombinant bacmids B1 to B4 using a PCR instrument to confirm that the recombinant bacmids B1 to B4, respectively, contained the dengue virus serotype I prME segment gene 122A1, the dengue virus serotype II prME segment gene 122A2, the dengue virus serotype III prME segment gene 122A3, and the dengue virus serotype IV prME segment gene 122A4. The recombinant bacmids were then sent for sequencing. As shown in FIG24 , the colony PCR products of recombinant bacmids B1, No. 1, No. 2, and No. 3, were 3792 bp in length, confirming that the recombinant bacmids B1 contained the dengue virus serotype I prME segment gene 122A1. As shown in Figure 25 , the colony PCR products of recombinant bacmids B2, numbered 1, 2, and 3, are 3792 bp in length, confirming that the recombinant bacmids B2 contain the serotype II dengue virus prME segment gene 122A2. As shown in Figure 26 , the colony PCR products of recombinant bacmids B3, numbered 1, 2, and 3, are 4122 bp in length, confirming that the recombinant bacmids B3 contain the serotype III dengue virus prME segment gene 122A3. As shown in Figure 27 , the colony PCR products of recombinant bacmids B4 are 7029 bp, 1016 bp, and 253 bp in length, confirming that the recombinant bacmids B4 contain the serotype IV dengue virus prME segment gene 122A4.

[0197] The Japanese encephalitis virus prME segment gene, including the precursor membrane protein segment gene and the envelope protein segment gene, was amplified using a PCR instrument with DNA polymerase and primers JEV-prME F and JEV-prME R listed in Table 2 using a plasmid containing the Japanese encephalitis virus prME segment gene 122A5 (constructed in the laboratory) to generate the Japanese encephalitis virus prME segment gene 122A5 (SEQ ID NO: 17) (as shown in FIG. 28 ).

[0198] Next, the recombinant bacmid A was cut with the XhoI and NheI restriction enzymes (7643 bp and 1272 bp after cleavage) to confirm sequence accuracy (as shown in FIG23 ). The Japanese encephalitis virus prME fragment gene 122A5 and the recombinant bacmid A were then ligated using a ligase, such that the Japanese encephalitis virus prME fragment gene 122A5 was ligated downstream of the p10 promoter of the recombinant bacmid A, between the p10 promoter and the right Tn7 transposon, to generate the recombinant bacmid B5 (SEQ ID NO: 22).

[0199] Furthermore, colony PCR was performed on the recombinant bacmid B5 using a PCR instrument to confirm that the recombinant bacmid B5 contained the Japanese encephalitis virus prME segment gene 122A5, and the recombinant bacmid B5 was then sent for sequencing. Figure 29 shows the colony PCR products of the recombinant bacmid B5, with lengths of 6510 bp, 1458 bp, 700 bp, and 253 bp, confirming that the recombinant bacmid B5 contained the Japanese encephalitis virus prME segment gene 122A5.

[0200] FIG30 is a schematic diagram of a recombinant bacmid B. Recombinant bacmid B can be recombinant bacmid B1, recombinant bacmid B2, recombinant bacmid B3, recombinant bacmid B4, or recombinant bacmid B5. The foreign protein gene 122 can be the prME segment gene 122A1 of the dengue virus serotype I, the prME segment gene 122A2 of the dengue virus serotype II, the prME segment gene 122A3 of the dengue virus serotype III, the prME segment gene 122A4 of the dengue virus serotype IV, or the prME segment gene 122A5 of the Japanese encephalitis virus.

[0201] In the recombinant bacmid B, the p10 promoter is connected downstream to the foreign protein gene 122, while the polH promoter is connected downstream to the recombinant expression protein gene 121. The recombinant expression protein gene 121 sequentially includes the GP64 signal peptide fragment gene 1211A, the SEAP fragment gene 1212a, and the GP64 transmembrane domain fragment gene 1211B.

[0202] Table 2

[0203] Example 2: Establishment of recombinant baculovirus

[0204] Using Bac-to-Bac TM Recombinant baculovirus C was generated using the Baculovirus Expression System (purchased from Thermo, product number 10359016) and recombinant baculovirus plasmid B. Recombinant baculovirus C was then infected into Sf21 cells and amplified using the Sf21 cells. The recombinant baculovirus C can be recombinant baculovirus C1, recombinant baculovirus C2, recombinant baculovirus C3, recombinant baculovirus C4, or recombinant baculovirus C5. Recombinant baculovirus C1 carries recombinant baculovirus plasmid B1, recombinant baculovirus C2 carries recombinant baculovirus plasmid B2, recombinant baculovirus C3 carries recombinant baculovirus plasmid B3, recombinant baculovirus C4 carries recombinant baculovirus plasmid B4, and recombinant baculovirus C5 carries recombinant baculovirus plasmid B5.

[0205] Next, a fluorescence microscope (purchased from Nikon) was used to confirm that recombinant baculovirus C had infected Sf21 cells. Because recombinant baculovirus plasmid B contains the mCherry gene, the red fluorescent signal emitted by the red fluorescent protein translated from the mCherry gene can be used to confirm whether recombinant baculovirus C has successfully carried recombinant baculovirus plasmid B and successfully infected Sf21 cells. As shown in Figure 31, the red fluorescent signals of recombinant baculovirus C1, C2, C3, C4, and C5, respectively, were detected when infected with Sf21 cells.

[0206] Next, a group of Sf21 cells not infected with the recombinant baculovirus was prepared as a control group, and an anti-dengue virus prM protein antibody (purchased from GeneTex, product number GTX128092, 1:500) was used as the primary antibody. 488 goat anti-rabbit IgG antibody (purchased from abcam, product number ab150077, 1:500) was used as a secondary antibody. Immunofluorescence (IF) staining confirmed that the dengue virus prME protein was expressed on the surface of recombinant baculovirus C in Sf21 cells. As shown in Figure 32, there are respectively the red fluorescence signal of the recombinant baculovirus C1 infected into Sf21 cells and the green fluorescence signal of the serotype I dengue virus prME protein expressed on the surface of the recombinant baculovirus C1 in the Sf21 cells; the red fluorescence signal of the recombinant baculovirus C2 infected into Sf21 cells and the green fluorescence signal of the serotype II dengue virus prME protein expressed on the surface of the recombinant baculovirus C2 in the Sf21 cells; the red fluorescence signal of the recombinant baculovirus C3 infected into Sf21 cells and the green fluorescence signal of the serotype III dengue virus prME protein expressed on the surface of the recombinant baculovirus C3 in the Sf21 cells; and the red fluorescence signal of the recombinant baculovirus C4 infected into Sf21 cells and the green fluorescence signal of the serotype IV dengue virus prME protein expressed on the surface of the recombinant baculovirus C4 in the Sf21 cells.

[0207] A group of Sf21 cells not infected with the recombinant baculovirus was prepared as a control group, and anti-Japanese encephalitis virus E protein antibody (purchased from GeneTex, product number GTX125867, 1:500) was used as the primary antibody. Immunofluorescence staining using 488 goat anti-rabbit IgG antibody (purchased from abcam, product number ab150077, 1:500) as a secondary antibody confirmed the expression of the Japanese encephalitis virus prME protein on the surface of recombinant baculovirus C in Sf21 cells. As shown in Figure 32 , the red fluorescence signal from recombinant baculovirus C5 infected with Sf21 cells and the green fluorescence signal from the Japanese encephalitis virus prME protein expressed on the surface of recombinant baculovirus C5 in Sf21 cells were detected.

[0208] The control group had neither the red fluorescent signal of the recombinant baculovirus nor the green fluorescent signal of the exogenous protein.

[0209] Example 3: Detection Kit Test Process

[0210] 1. Antibody Coating

[0211] (1) Prepare the coating buffer according to the coating buffer recipe in Table 3.

[0212] Table 3

[0213] (2) Dilute the antibody with coating buffer at a dilution ratio of 1:250. The antibody can be anti-dengue virus E protein antibody (purchased from GeneTex, product number GTX127277), anti-dengue virus prM protein antibody (purchased from GeneTex, product number GTX128092), anti-Japanese encephalitis virus E protein antibody (purchased from GeneTex, product number GTX125867), or anti-GP64 antibody (purchased from Abcam, product number Ab91214).

[0214] (3) Add 100 μL of diluted antibody to each well of the plate.

[0215] (4) Incubate at 4°C overnight to complete antibody coating.

[0216] 2. Antibody Fixation

[0217] (1) Remove the diluted antibody and add 200 μL of 1X PBS to each well. Rinse for 5 minutes at room temperature three times.

[0218] (2) Add 150 μL of fixation buffer (1X PBS containing 1% BSA) to each well.

[0219] (3) Incubate at 37°C for 90 minutes to complete antibody fixation.

[0220] 3. Add test samples

[0221] (1) Remove the fixation buffer and add 200 μL of washing buffer (1X PBS containing 0.05% Tween 20) to each well. Rinse for 5 minutes three times at room temperature.

[0222] (2) Add 100 μL of diluted recombinant baculovirus C. The diluted recombinant baculovirus C was diluted 104 times with 1X PBS.

[0223] (3) After incubation at 27°C for 2 hours, the supernatant was removed. 200 μL of washing buffer (1X PBS containing 0.05% Tween 20) was added to each well and the cells were rinsed three times for 5 minutes at room temperature.

[0224] 4. Detection of SEAP Activity

[0225] GreatEscAPe TM SEAP detection kit (purchased from Takara) was used for detection.

[0226] (1) Dilute 5X dilution buffer 5-fold with pure water to obtain 1X dilution buffer.

[0227] (2) Add 100 μL of 1X dilution buffer to each well.

[0228] (3) Add 100 μL of SEAP substrate solution warmed to room temperature to each well.

[0229] (4) Incubate at room temperature for 30 minutes.

[0230] (5) Use a cold light meter to measure the relative light unit (RLU) of each well to obtain the SEAP activity test results.

[0231] Example 4: Comparative test of anti-dengue virus E protein antibodies and anti-dengue virus prM protein antibodies in the test kit

[0232] A comparative test was conducted using the test kit test process described in Example 3. During the antibody coating step, the coated antibody was either an anti-dengue virus E protein antibody or an anti-dengue virus prM protein antibody. Furthermore, during the test sample addition step, the blank group received no sample; control group A1 received approximately 1x10⁶ PFU (Plaque Forming Units) of a recombinant baculovirus expressing only the serotype II dengue virus prME protein; experimental group A received approximately 1x10⁶ PFU of recombinant baculovirus C2 (a recombinant baculovirus expressing both SEAP and the serotype II dengue virus prME protein); and control group A2 received approximately 1x10⁶ PFU of a recombinant baculovirus expressing only SEAP.

[0233] Referring to Figure 33 , in experimental group A, anti-dengue virus E protein antibodies exhibited higher SEAP activity than anti-dengue virus prM protein antibodies. This suggests that anti-dengue virus E protein antibodies should be able to better recognize and bind to the serotype II dengue virus prME protein expressed on the surface of recombinant baculovirus C2.

[0234] Example 5: Comparative test of virus titer of detection kit

[0235] A comparative test was conducted using the test kit test process described in Example 3. During the antibody coating step, the coated antibody was an anti-dengue virus E protein antibody. Furthermore, during the test sample addition step, no sample was added to the blank group; control group A was supplemented with approximately 1x10⁶ PFU of a recombinant baculovirus expressing only the serotype II dengue virus prME protein; experimental group A1 was supplemented with approximately 1x10⁶ PFU of recombinant baculovirus C2 (a recombinant baculovirus C expressing both SEAP and the serotype II dengue virus prME protein); experimental group A2 was supplemented with approximately 1x10⁴ PFU of recombinant baculovirus C2; and experimental group A3 was supplemented with approximately 1x10⁰ PFU of recombinant baculovirus C2.

[0236] Referring to Figure 34 , experimental groups A1 and A2 exhibited higher SEAP activity compared to the blank group and control group A. Furthermore, experimental group A1 exhibited the highest SEAP activity. This suggests that a viral titer of 1x10⁴ to 1x10⁶ PFU should be the optimal viral titer (viral quantity) for the test kit. Furthermore, a viral titer of 1x10⁶ PFU should be the optimal viral titer for the test kit.

[0237] Example 6: Comparative Test I of Detection Kit Specificity

[0238] A comparative test was conducted using the test kit test process described in Example 3. In the antibody coating step, the coated antibodies were anti-dengue virus E protein antibodies, anti-Japanese encephalitis virus E protein antibodies, or anti-GP64 antibodies. Furthermore, in the test sample addition step, control group C was supplemented with approximately 1x10⁶ PFU of baculovirus (baculovirus not transfected with a recombinant baculovirus plasmid); experimental group A was supplemented with approximately 1x10⁶ PFU of recombinant baculovirus C2 (a recombinant baculovirus C expressing both SEAP and the prME protein of serotype II dengue virus); and experimental group B was supplemented with approximately 1x10⁶ PFU of recombinant baculovirus C5 (a recombinant baculovirus C expressing both SEAP and the prME protein of Japanese encephalitis virus).

[0239] As shown in Figure 35 , antibodies against dengue virus E protein can effectively identify recombinant baculovirus expressing serotype II dengue virus prME protein, while antibodies against Japanese encephalitis virus E protein can effectively identify recombinant baculovirus expressing Japanese encephalitis virus prME protein. This demonstrates that the corresponding antibodies effectively recognize the corresponding antigens, and the test kit can be used as a method for detecting dengue virus or Japanese encephalitis virus.

[0240] Example 7: Comparative Test II of Detection Kit Specificity

[0241] The test kit test process of Example 3 was used for comparative testing. In the antibody coating step, the coated antibody was an anti-dengue virus E protein antibody or an anti-Japanese encephalitis virus E protein antibody. In addition, in the test sample addition step, no sample was added to the blank group; the control group A was added with about 1x10 6 PFU of recombinant baculovirus expressing only serotype II dengue virus prME protein; experimental group A added about 1x10 6 PFU of recombinant baculovirus C2 (recombinant baculovirus C expressing both SEAP and serotype II dengue virus prME protein); control group B was supplemented with approximately 1x10 6 PFU of recombinant baculovirus expressing only Japanese encephalitis virus prME protein; while experimental group B added about 1x10 6 PFU of recombinant baculovirus C5 (recombinant baculovirus C expressing both SEAP and Japanese encephalitis virus prME proteins).

[0242] Referring to Figure 36 , antibodies against the Japanese encephalitis virus E protein can effectively identify recombinant baculovirus expressing the Japanese encephalitis virus prME protein, as well as recombinant baculovirus expressing the serotype II dengue virus prME protein. This demonstrates that, because Japanese encephalitis virus and dengue virus belong to the same family of viruses called Flaviviridae, cross-reactivity exists between the antigens and antibodies against these two viruses, and that the Japanese encephalitis virus antigen expressed on the recombinant baculovirus has a higher specificity with the antibody.

[0243] Example 8: Detection Kit

[0244] The test kit was tested using the test kit test process described in Example 3. During the antibody coating step, the coated antibody was an anti-dengue virus E protein antibody at a dilution ratio of 1:500 or 1:1000. Furthermore, during the test sample addition step, recombinant baculovirus C2 (a recombinant baculovirus C expressing both SEAP and the prME protein of serotype II dengue virus) was added to experimental group A, while recombinant baculovirus C5 (a recombinant baculovirus C expressing both SEAP and the prME protein of Japanese encephalitis virus) was added to experimental group B.

[0245] Referring to Figure 37 , anti-dengue virus E protein antibodies, tested at a 1:500 dilution, showed strong recognition of recombinant baculovirus expressing the prME protein of serotype II dengue virus. Referring to Figure 38 , anti-dengue virus E protein antibodies, tested at a 1:1000 dilution, also showed strong recognition of recombinant baculovirus expressing the prME protein of serotype II dengue virus. This demonstrates that the test kit can be used as a method for detecting dengue virus.

[0246] Example 9: Microfluidic System

[0247] Referring to Figure 39 , the microfluidic system M1 includes a microfluidic module 300 and a buffer liquid. The microfluidic module 300 comprises a first transmission trough 31A, a sample chamber 32, a filtration chamber 33, a microfluidic channel 34, a second transmission trough 31B, a buffer chamber 35A, a sensing chamber 36, a capture layer 361, a chipset 362, and a waste chamber 37. The sample chamber 32 has an inlet 321 connected to the first transmission trough 31A. The analyte enters the sample chamber 32 through the inlet 321, and the sample chamber 32 is used to hold the analyte. In this embodiment, the analyte is blood. The microfluidic channel 34 connects the sample chamber 32 and the filtration chamber 33 and is located between them. The buffer chamber 35A connects to the second transmission trough 31B and is used to hold the buffer liquid. The sensing chamber 36 connects the filtration chamber 33 and the buffer chamber 35A and is located between them. Chipset 362 is located at the bottom of the inner surface of sensing chamber 36. Capture layer 361 is coated on the inner surface of sensing chamber 36. The recombinant baculovirus envelope in capture layer 361 is pierced with antigens. A waste chamber 37 is connected to sensing chamber 36. Buffer liquid is contained in buffer chamber 35A.

[0248] The chipset 362 includes a first biosensor chip BC1 and a second biosensor chip BC2 . The first biosensor chip BC1 is coated with a capture layer 361 (as shown in FIG. 40 ), while the second biosensor chip BC2 is not coated with the capture layer 361 .

[0249] Furthermore, pistons or pumps are placed in the first transmission groove 31A and the second transmission groove 31B.

[0250] Furthermore, the inner wall 341 of the microchannel 34 has an antibody coating 342 , and the antibody coating 342 includes Anti-D antibodies (see FIG. 17 ).

[0251] The following describes the operation process of the microfluidic system M1:

[0252] Step 1: The analyte (blood) enters the sample chamber 32 through the injection port 321 , and the injection port 321 is closed.

[0253] Step 2: A piston or pump located in first transmission channel 31A pressurizes air, pushing the analyte from sample chamber 32 into microfluidic channel 34. Antibody coating 342 on inner wall 341 of microfluidic channel 34 rapidly aggregates and precipitates red blood cells. After aggregation and precipitation, the analyte becomes plasma or serum.

[0254] Step 3: The plasma or serum is passed into the filtration chamber 33, where its porous membrane filters out any remaining red blood cells or debris. The plasma or serum is then passed into the sensing chamber 36. Antibodies (antigen-specific) in the plasma or serum bind to the antigens on the surface of the recombinant baculovirus in the capture layer 361 coated on the first biosensor chip BC1 (as shown in FIG41 ), but do not bind to the second biosensor chip BC2. The electronic signals from the first and second biosensor chips BC1 and BC2 are detected simultaneously.

[0255] Step 4: A piston or pump located in the second transmission channel 31B pressurizes the air, pushing the cleaning buffer liquid from the buffer chamber 35B into the sensing chamber 36, washing away antibodies or other biomolecules not bound to the recombinant baculovirus. The liquid then flows to the waste chamber 37. The electronic signals of the first biosensor chip BC1 and the second biosensor chip BC2 are continuously and synchronously detected.

[0256] Step 5: After the reaction reaches equilibrium, calculate the electronic signals (Ids, drain-to-source current) generated by the first biosensor chip BC1 and the second biosensor chip BC2, and their difference (ΔI). This difference is the electronic signal contributed by the antibody Ab, as shown in Figure 46.

[0257] Example 10: Microfluidic System

[0258] The microfluidic system M1 of Example 10 is substantially the same as the microfluidic system M1 of Example 9, except that the envelope of the recombinant baculovirus in the capture layer 361 is provided with IgG antibodies instead of antigens (as shown in FIG. 42 ).

[0259] The following describes the operation process of the microfluidic system M1:

[0260] Step 1: The analyte (blood) enters the sample chamber 32 through the injection port 321 , and the injection port 321 is closed.

[0261] Step 2: A piston or pump located in first transmission channel 31A pressurizes air, pushing the analyte from sample chamber 32 into microfluidic channel 34. Antibody coating 342 on inner wall 341 of microfluidic channel 34 rapidly aggregates and precipitates red blood cells. The analyte after red blood cell aggregation and precipitation is plasma or serum.

[0262] Step 3: The plasma or serum is passed into the filtration chamber 33, where its porous membrane filters out any remaining red blood cells or debris. The plasma or serum is then passed into the sensing chamber 36. The antigens (antigens corresponding to IgG antibodies) in the plasma or serum bind to the IgG antibodies on the surface of the recombinant baculovirus in the capture layer 361 coated on the first biosensor chip BC1 (as shown in Figure 43), but not to the second biosensor chip BC2. The electronic signals from the first and second biosensor chips BC1 and BC2 are detected simultaneously.

[0263] Step 4: The piston or pump located in the second transmission channel 31B pressurizes the air, pushing the cleaning buffer liquid from the buffer chamber 35B into the sensing chamber 36, washing away antigens or other biomolecules not bound to the recombinant baculovirus and flowing them into the waste chamber 37. The electronic signals of the first biosensor chip BC1 and the second biosensor chip BC2 are continuously and synchronously detected.

[0264] Step 5: After the reaction reaches equilibrium, calculate the electronic signals (Ids, drain-to-source current) generated by the first biosensor chip BC1 and the second biosensor chip BC2, and their difference (ΔI). This difference is the electronic signal contributed by the antigen Ag, as shown in Figure 46.

[0265] Example 11: Microfluidic System

[0266] The microfluidic system M1 of Example 11 is substantially the same as the microfluidic system M1 of Example 9, except that the envelope of the recombinant baculovirus in the capture layer 361 is coated with protein A, protein G, or a combination of protein A and protein G, rather than antigen. Protein A, protein G, or a combination of protein A and protein G binds to IgG antibodies (as shown in FIG. 44 ).

[0267] The following describes the operation process of the microfluidic system M1:

[0268] Step 1: The analyte (blood) enters the sample chamber 32 through the injection port 321 , and the injection port 321 is closed.

[0269] Step 2: A piston or pump located in first transmission channel 31A pressurizes air, pushing the analyte from sample chamber 32 into microfluidic channel 34. Antibody coating 342 on inner wall 341 of microfluidic channel 34 rapidly aggregates and precipitates red blood cells. The analyte after red blood cell aggregation and precipitation is plasma or serum.

[0270] Step 3: The plasma or serum is passed into the filtration chamber 33, where its porous membrane filters out any remaining red blood cells or debris. The plasma or serum is then passed into the sensing chamber 36. Antigens (antigens corresponding to IgG antibodies) in the plasma or serum bind to IgG antibodies bound to the recombinant baculovirus surface in the capture layer 361 coated on the first biosensor chip BC1 (as shown in FIG45 ), but not to the second biosensor chip BC2. The electronic signals from the first and second biosensor chips BC1 and BC2 are detected simultaneously.

[0271] Step 4: The piston or pump located in the second transmission channel 31B pressurizes the air, pushing the cleaning buffer liquid from the buffer chamber 35B into the sensing chamber 36, washing away antigens or other biomolecules not bound to the recombinant baculovirus and flowing them into the waste chamber 37. The electronic signals of the first biosensor chip BC1 and the second biosensor chip BC2 are continuously and synchronously detected.

[0272] Step 5: After the reaction reaches equilibrium, calculate the electronic signals (Ids, drain-to-source current) generated by the first biosensor chip BC1 and the second biosensor chip BC2, and their difference (ΔI). This difference is the electronic signal contributed by the antigen Ag, as shown in Figure 46.

[0273] Example 12: Microfluidic System

[0274] Referring to Figure 47 , the microfluidic system M1 includes a microfluidic module 300, a buffer liquid, a second buffer liquid, and a probe 381. The microfluidic module 300 includes a first transfer slot 31A, a sample chamber 32, a filter chamber 33, a microfluidic channel 34, a second transfer slot 31B, a buffer chamber 35A, a sensing chamber 36, a capture layer 361, a chipset 362, a waste chamber 37, a third transfer slot 31C, a probe chamber 38, a fourth transfer slot 31D, and a second buffer chamber 35B. The sample chamber 32 has an inlet 321 connected to the first transfer slot 31A. The analyte enters the sample chamber 32 through the inlet 321, and the sample chamber 32 is used to accommodate the analyte. In this embodiment, the analyte is blood. The microfluidic channel 34 connects the sample chamber 32 and the filter chamber 33 and is located between them. The buffer chamber 35A is connected to the second transfer slot 31B and is used to accommodate the buffer liquid. The sensing chamber 36 connects the filter chamber 33 and the buffer chamber 35A and is located between the filter chamber 33 and the buffer chamber 35A. The chipset 362 is located at the bottom of the inner surface of the sensing chamber 36. The capture layer 361 is coated on the inner surface of the sensing chamber 36, and the envelope of the recombinant baculovirus in the capture layer 361 is provided with antigens. The waste chamber 37 connects the sensing chamber 36. The probe chamber 38 connects the third transmission groove 31C and the sensing chamber 36 and is located between the third transmission groove 31C and the sensing chamber 36. The probe chamber 38 is used to accommodate a probe 381. The second buffer chamber 35B connects the fourth transmission groove 31D and the sensing chamber 36 and is used to accommodate a second buffer liquid. The buffer liquid is accommodated in the buffer chamber 35A. The probe 381 is accommodated in the probe chamber 38. The second buffer liquid is accommodated in the second buffer chamber 35B.

[0275] The chipset 362 includes a first biosensor chip BC1 and a second biosensor chip BC2 . The first biosensor chip BC1 is coated with a capture layer 361 (as shown in FIG. 48 ), while the second biosensor chip BC2 is not coated with a capture layer 361 .

[0276] Furthermore, pistons or pumps are placed in the first transmission groove 31A, the second transmission groove 31B, the third transmission groove 31C, and the fourth transmission groove 31D.

[0277] Furthermore, the inner wall 341 of the microchannel 34 has an antibody coating 342 , and the antibody coating 342 includes Anti-D antibodies (see FIG. 17 ).

[0278] The following describes the operation process of the microfluidic system M1:

[0279] Step 1: The analyte (blood) enters the sample chamber 32 through the injection port 321 , and the injection port 321 is closed.

[0280] Step 2: A piston or pump located in first transmission channel 31A pressurizes air, pushing the analyte from sample chamber 32 into microfluidic channel 34. Antibody coating 342 on inner wall 341 of microfluidic channel 34 rapidly aggregates and precipitates red blood cells. The analyte after red blood cell aggregation and precipitation is plasma or serum.

[0281] Step 3: The plasma or serum is pushed into the filtration chamber 33, where the porous membrane filters out any remaining red blood cells or debris. The plasma or serum is then pushed into the sensing chamber 36. Antibodies (Ab) in the plasma or serum (corresponding to the antigen) bind to the antigens on the surface of the recombinant baculovirus in the capture layer 361 coated on the first biosensor chip BC1 (as shown in FIG49 ), but do not bind to the second biosensor chip BC2.

[0282] Step 4: The piston or pump located in the second transmission groove 31B pressurizes the air to push the cleaning buffer liquid from the buffer chamber 35B to the sensing chamber 36 to wash away the antibodies or other biomolecules that are not bound to the recombinant baculovirus and flow to the waste chamber 37.

[0283] Step 5: The piston or pump located in the third transmission slot 31C pressurizes the air, pushing the probe 381 from the probe chamber 38 to the sensing chamber 36. The probe 381 binds to the antibody Ab bound to the recombinant baculovirus (as shown in FIG49 ). The optical signals from the first biosensor chip BC1 and the second biosensor chip BC2 are detected simultaneously.

[0284] Step 6: The piston or pump located in the fourth transmission slot 31D pressurizes the air, pushing the second buffer liquid for cleaning from the second buffer chamber 35B into the sensing chamber 36. This washes away the probes 381 or other biomolecules that have not bound to the antibody Ab, and then flows to the waste chamber 37. The optical signals from the first biosensor chip BC1 and the second biosensor chip BC2 are continuously and synchronously detected.

[0285] Step 7: After the reaction reaches equilibrium, the difference in optical signals generated by the first biosensor chip BC1 and the second biosensor chip BC2 is calculated to represent the optical signal contributed by the antibody Ab. Figure 50 shows a line graph showing a positive correlation between the difference in optical signals generated by the first biosensor chip BC1 and the second biosensor chip BC2 and the antibody Ab concentration.

[0286] Example 13: Microfluidic System

[0287] The microfluidic system M1 of Example 13 is substantially the same as the microfluidic system M1 of Example 12, except that the envelope of the recombinant baculovirus in the capture layer 361 is provided with antibodies instead of antigens (as shown in FIG. 51 ).

[0288] The following describes the operation process of the microfluidic system M1:

[0289] Step 1: The analyte (blood) enters the sample chamber 32 through the injection port 321 , and the injection port 321 is closed.

[0290] Step 2: A piston or pump located in first transmission channel 31A pressurizes air, pushing the analyte from sample chamber 32 into microfluidic channel 34. Antibody coating 342 on inner wall 341 of microfluidic channel 34 rapidly aggregates and precipitates red blood cells. The analyte after red blood cell aggregation and precipitation is plasma or serum.

[0291] Step 3: The plasma or serum is pushed into the filtration chamber 33, where the porous membrane filters out any remaining red blood cells or debris. The plasma or serum is then pushed into the sensing chamber 36. Antigens (antibodies) in the plasma or serum bind to antibodies on the surface of the recombinant baculovirus in the capture layer 361 coated on the first biosensor chip BC1 (as shown in FIG52 ), but do not bind to the second biosensor chip BC2.

[0292] Step 4: The piston or pump located in the second transmission groove 31B pressurizes the air to push the cleaning buffer liquid from the buffer chamber 35B to the sensing chamber 36 to wash away the antigens or other biomolecules not bound to the recombinant baculovirus and flow to the waste chamber 37.

[0293] Step 5: The piston or pump located in the third transmission channel 31C pressurizes the air, pushing the probe 381 from the probe chamber 38 to the sensing chamber 36. The probe 381 binds to the antigen Ag bound to the recombinant baculovirus (as shown in FIG52 ). The optical signals from the first biosensor chip BC1 and the second biosensor chip BC2 are detected simultaneously.

[0294] Step 6: The piston or pump located in the fourth transmission slot 31D pressurizes the air, pushing the second buffer liquid for cleaning from the second buffer chamber 35B into the sensing chamber 36. This washes away the probes 381 or other biomolecules that have not bound to the antigen Ag, and then flows to the waste chamber 37. The optical signals from the first biosensor chip BC1 and the second biosensor chip BC2 are continuously and synchronously detected.

[0295] Step 7: After the reaction reaches equilibrium, the difference in optical signals generated by the first biosensor chip BC1 and the second biosensor chip BC2 is calculated to represent the optical signal contributed by the antigen Ag. Figure 55 shows a line graph showing a positive correlation between the difference in optical signals generated by the first biosensor chip BC1 and the second biosensor chip BC2 and the antigen Ag concentration.

[0296] Example 14: Microfluidic System

[0297] The microfluidic system M1 of Example 14 is substantially the same as the microfluidic system M1 of Example 12, except that the envelope of the recombinant baculovirus in the capture layer 361 is coated with protein A, protein G, or a combination of protein A and protein G, rather than an antigen. Protein A, protein G, or a combination of protein A and protein G binds to an antibody (as shown in FIG. 53 ).

[0298] The following describes the operation process of the microfluidic system M1:

[0299] Step 1: The analyte (blood) enters the sample chamber 32 through the injection port 321 , and the injection port 321 is closed.

[0300] Step 2: A piston or pump located in first transmission channel 31A pressurizes air, pushing the analyte from sample chamber 32 into microfluidic channel 34. Antibody coating 342 on inner wall 341 of microfluidic channel 34 rapidly aggregates and precipitates red blood cells. The analyte after red blood cell aggregation and precipitation is plasma or serum.

[0301] Step 3: The plasma or serum is pushed into the filtration chamber 33, where the porous membrane filters out any remaining red blood cells or debris. The plasma or serum is then pushed into the sensing chamber 36. Antigens (antibodies) in the plasma or serum bind to antibodies bound to the recombinant baculovirus surface in the capture layer 361 coated on the first biosensor chip BC1 (as shown in FIG54 ), but do not bind to the second biosensor chip BC2.

[0302] Step 4: The piston or pump located in the second transmission groove 31B pressurizes the air to push the cleaning buffer liquid from the buffer chamber 35B to the sensing chamber 36 to wash away the antigens or other biomolecules not bound to the recombinant baculovirus and flow to the waste chamber 37.

[0303] Step 5: The piston or pump located in the third transmission channel 31C pressurizes the air, pushing the probe 381 from the probe chamber 38 to the sensing chamber 36. The probe 381 binds to the antigen Ag bound to the recombinant baculovirus (as shown in FIG54). The optical signals from the first biosensor chip BC1 and the second biosensor chip BC2 are detected simultaneously.

[0304] Step 6: The piston or pump located in the fourth transmission slot 31D pressurizes the air, pushing the second buffer liquid for cleaning from the second buffer chamber 35B into the sensing chamber 36. This washes away the probes 381 or other biomolecules that have not bound to the antigen Ag, and then flows to the waste chamber 37. The optical signals from the first biosensor chip BC1 and the second biosensor chip BC2 are continuously and synchronously detected.

[0305] Step 7: After the reaction reaches equilibrium, the difference in optical signals generated by the first biosensor chip BC1 and the second biosensor chip BC2 is calculated to represent the optical signal contributed by the antigen Ag. Figure 55 shows a line graph showing a positive correlation between the difference in optical signals generated by the first biosensor chip BC1 and the second biosensor chip BC2 and the antigen Ag concentration.

[0306] Example 15: Microfluidic System

[0307] Referring to Figure 56 , the microfluidic system M2 includes a microfluidic module 400, a recombinant baculovirus 100, and a buffer liquid. The microfluidic module 400 includes a first transfer slot 41A, a sample chamber 42, a filtration chamber 43, a microfluidic channel 44, a second transfer slot 41B, a virus chamber 48, a reaction chamber 49, a third transfer slot 41C, a buffer chamber 45, a sensing chamber 46, a capture layer 461, a chipset 462, and a waste chamber 47. The sample chamber 42 has an inlet 421 connected to the first transfer slot 41A. The analyte enters the sample chamber 42 through the inlet 421, and the sample chamber 42 is used to hold the analyte. In this embodiment, the analyte is blood. The microfluidic channel 44 connects the sample chamber 42 and the filtration chamber 43 and is located between them. The virus chamber 48 is connected to the second transfer slot 41B and is used to hold the recombinant baculovirus 100. Reaction chamber 49 connects to filtration chamber 43 and virus chamber 48, and is located between them. Buffer chamber 45 is connected to third transmission slot 41C and is used to accommodate buffer liquid. Sensing chamber 46 connects to reaction chamber 49 and buffer chamber 45, and is located between them. Chipset 462 is located at the bottom of the inner surface of sensing chamber 46. Capture layer 461 is coated on the inner surface of sensing chamber 46 and includes antibodies. Waste chamber 47 is connected to sensing chamber 46. Buffer liquid is accommodated in buffer chamber 45. Recombinant baculovirus 100 is accommodated in virus chamber 48.

[0308] The antibody in the capture layer 461 is an anti-human IgG or IgM antibody.

[0309] Furthermore, antigens and reporter proteins are embedded on the envelope of the recombinant baculovirus 100 (as shown in FIG57 ). The reporter protein can be a fluorescent protein, AP, or HRP.

[0310] Furthermore, the chipset 462 includes a first biosensing chip BC1 and a second biosensing chip BC2 . The first biosensing chip BC1 is coated with a capture layer 461 (as shown in FIG. 59 ), while the second biosensing chip BC2 is not coated with a capture layer 461 .

[0311] Furthermore, pistons or pumps are placed in the first transmission groove 41A, the second transmission groove 41B, and the third transmission groove 41C.

[0312] The following describes the operation process of the microfluidic system M2:

[0313] Step 1: The analyte (blood) enters the sample chamber 42 through the injection port 421 , and the injection port 421 is closed.

[0314] Step 2: The piston or pump located in the first transmission groove 41A pressurizes the air to push the analyte from the sample chamber 42 to the microchannel 44 for red blood cell aggregation and sedimentation. The analyte that has undergone red blood cell aggregation and sedimentation is plasma or serum.

[0315] Step 3: The plasma or serum is pushed into the filter chamber 43 , where the remaining red blood cells or debris are filtered out by the porous filter membrane of the filter chamber 43 . Next, the plasma or serum is pushed into the reaction chamber 49 .

[0316] Step 4: The piston or pump located in the second transmission groove 41B pressurizes the air, pushing the recombinant baculovirus 100 from the virus chamber 48 to the reaction chamber 49. The antibodies Ab (corresponding to the antigen) in the plasma or serum will bind to the antigen on the surface of the recombinant baculovirus 100 (as shown in Figures 57 and 58).

[0317] Step 5: The recombinant baculovirus 100 and antibody Ab bound in the reaction chamber 49 flow into the sensing chamber 46. The antibody Ab (bound to the recombinant baculovirus 100) binds to the anti-human IgG or IgM antibody in the capture layer 461 coated on the first biosensor chip BC1 (as shown in FIG59 ), but does not bind to the second biosensor chip BC2. The electronic or optical signals from the first and second biosensor chips BC1 and BC2 are simultaneously detected. In some embodiments, the optical signal is obtained by detecting the expression of a reporter protein on the surface of the recombinant baculovirus 100.

[0318] Step 6: The piston or pump located in the third transmission channel 41C pressurizes the air, pushing the cleaning buffer liquid from the buffer chamber 45 into the sensing chamber 46, washing away the antibodies or other biomolecules not bound to the anti-human IgG or IgM antibodies, and then flowing them to the waste chamber 47. The electronic or optical signals of the first biosensor chip BC1 and the second biosensor chip BC2 are continuously and synchronously detected.

[0319] Step 7: After the reaction reaches equilibrium, the difference between the electronic signal or optical signal generated by the first biosensor chip BC1 and the second biosensor chip BC2 is calculated, which is the electronic signal or optical signal contributed by the antibody Ab (see FIG. 46 or FIG. 50 ).

[0320] In this embodiment, since the recombinant baculovirus 100 expresses both the reporter protein and the antigen, the reporter protein on the surface of the recombinant baculovirus 100 can be used as a secondary antibody, and detection can be performed without the need to add or use a secondary antibody or other probe.

[0321] Example 16: Microfluidic System

[0322] The microfluidic system M2 of Example 16 is substantially the same as the microfluidic system M2 of Example 15, except that the envelope of the recombinant baculovirus 100 is provided with antibodies and reporter proteins instead of antigens and reporter proteins (as shown in FIG. 60 ).

[0323] The following describes the operation process of the microfluidic system M2:

[0324] Step 1: The analyte (blood) enters the sample chamber 42 through the injection port 421 , and the injection port 421 is closed.

[0325] Step 2: The piston or pump located in the first transmission groove 41A pressurizes the air to push the analyte from the sample chamber 42 to the microchannel 44 for red blood cell aggregation and sedimentation. The analyte that has undergone red blood cell aggregation and sedimentation is plasma or serum.

[0326] Step 3: The plasma or serum is pushed into the filter chamber 43 , where the remaining red blood cells or debris are filtered out by the porous filter membrane of the filter chamber 43 . Next, the plasma or serum is pushed into the reaction chamber 49 .

[0327] Step 4: The piston or pump located in the second transmission groove 41B pressurizes the air, pushing the recombinant baculovirus 100 from the virus chamber 48 to the reaction chamber 49. The antigen Ag (corresponding to the antibody) in the plasma or serum binds to the antibody on the surface of the recombinant baculovirus 100 (as shown in Figures 60 and 61).

[0328] Step 5: The recombinant baculovirus 100 and antigen Ag bound in the reaction chamber 49 flow into the sensing chamber 46. The antigen Ag (bound to the recombinant baculovirus 100) binds to the anti-human IgG or IgM antibody in the capture layer 461 coated on the first biosensor chip BC1 (as shown in FIG62 ), but does not bind to the second biosensor chip BC2. The electronic or optical signals from the first and second biosensor chips BC1 and BC2 are simultaneously detected. In some embodiments, the optical signal is obtained by detecting the expression of a reporter protein on the surface of the recombinant baculovirus 100.

[0329] Step 6: The piston or pump located in the third transmission channel 41C pressurizes the air, pushing the cleaning buffer liquid from the buffer chamber 45 into the sensing chamber 46, washing away antigens or other biomolecules not bound to the anti-human IgG or IgM antibodies and then flowing them to the waste chamber 47. The electronic or optical signals of the first biosensor chip BC1 and the second biosensor chip BC2 are continuously and synchronously detected.

[0330] Step 7: After the reaction reaches equilibrium, the difference between the electronic signal or optical signal generated by the first biosensor chip BC1 and the second biosensor chip BC2 is calculated, which is the electronic signal or optical signal contributed by the antigen Ag (see FIG. 46 or FIG. 55 ).

[0331] In this embodiment, since the recombinant baculovirus 100 expresses both the reporter protein and the antibody, the reporter protein on the surface of the recombinant baculovirus 100 can be used as a secondary antibody, and detection can be performed without the need to add or use a secondary antibody or other probes.

[0332] Example 17: Microfluidic System

[0333] Referring to Figure 63, the microfluidic system M3 includes a microfluidic module 500, a recombinant baculovirus 100, a buffer liquid, and a second buffer liquid. The microfluidic module 500 includes a first transfer slot 51A, a sample chamber 52, a filtration chamber 53, a microfluidic channel 54, a second transfer slot 51B, a buffer chamber 55A, a third transfer slot 51C, a virus chamber 58, a sensing chamber 56, a capture layer 561, a chipset 562, a waste chamber 57, a fourth transfer slot 51D, and a second buffer chamber 55B. The sample chamber 52 has an inlet 521 connected to the first transfer slot 51A. The analyte enters the sample chamber 52 through the inlet 521, and the sample chamber 52 is used to accommodate the analyte. In this embodiment, the analyte is blood. The microfluidic channel 54 connects the sample chamber 52 and the filtration chamber 53 and is located between them. The buffer chamber 55A is connected to the second transfer slot 51B and is used to accommodate the buffer liquid. The virus chamber 58 is connected to the third transmission slot 51C and is used to accommodate the recombinant baculovirus 100. The sensing chamber 56 is connected to the filter chamber 53, the buffer chamber 55A, and the virus chamber 58, and is located between the filter chamber 53, the buffer chamber 55A, and the virus chamber 58. The chipset 562 is located at the bottom of the inner surface of the sensing chamber 56. The capture layer 561 is coated on the inner surface of the sensing chamber 56 and includes antibodies. The waste chamber 57 is connected to the sensing chamber 56. The second buffer chamber 55B is connected to the fourth transmission slot 51D and the sensing chamber 56 and is used to accommodate a second buffer liquid. The buffer liquid is accommodated in the buffer chamber 55A. The recombinant baculovirus 100 is accommodated in the virus chamber 58. The second buffer liquid is accommodated in the second buffer chamber 55B.

[0334] The envelope of the recombinant baculovirus 100 is provided with a reporter protein and protein A, protein G, or a combination of protein A and protein G (as shown in FIG66 ). Protein A, protein G, or a combination of protein A and protein G binds to an antibody. The reporter protein can be a fluorescent protein, AP, or HRP.

[0335] Furthermore, the chipset 562 includes a first biosensing chip BC1 and a second biosensing chip BC2 . The first biosensing chip BC1 is coated with a capture layer 561 (as shown in FIG. 64 ), while the second biosensing chip BC2 is not coated with a capture layer 561 .

[0336] Furthermore, pistons or pumps are placed in the first transmission groove 51A, the second transmission groove 51B, the third transmission groove 51C, and the fourth transmission groove 51D.

[0337] The following describes the operation process of the microfluidic system M3:

[0338] Step 1: The analyte (blood) enters the sample chamber 52 through the injection port 521 , and the injection port 521 is closed.

[0339] Step 2: The piston or pump located in the first transmission groove 51A pressurizes the air to push the analyte from the sample chamber 52 to the microchannel 54 for red blood cell aggregation and sedimentation. The analyte that has undergone red blood cell aggregation and sedimentation is plasma or serum.

[0340] Step 3: The plasma or serum is pushed into the filtration chamber 53, where the porous membrane filters out residual red blood cells and debris. The plasma or serum is then pushed into the sensing chamber 56. Antigens (antibodies) in the plasma or serum bind to the antibodies in the capture layer 561 coated on the first biosensor chip BC1 (as shown in FIG65 ), but do not bind to the second biosensor chip BC2.

[0341] Step 4: The piston or pump located in the second transmission groove 51B pressurizes the air to push the buffer liquid for cleaning from the buffer chamber 55A to the sensing chamber 56, washing away the antigens or other biomolecules not bound to the antibody, and flowing to the waste chamber 57.

[0342] Step 5: Air is pressurized using a piston or pump located in the third transmission channel 51C, pushing the recombinant baculovirus 100 from the virus chamber 58 to the sensing chamber 56. Antibodies bound to the surface of the recombinant baculovirus 100 bind to the antigen Ag (which is already bound to the antibodies in the capture layer 561 coated on the first biosensor chip BC1) (as shown in FIG66 ), but do not bind to the second biosensor chip BC2. The electronic or optical signals from the first and second biosensor chips BC1 and BC2 are simultaneously detected. In some embodiments, the optical signal is obtained by detecting the expression of a reporter protein on the surface of the recombinant baculovirus 100.

[0343] Step 6: The piston or pump located in the fourth transmission channel 51D pressurizes the air, pushing the cleaning buffer liquid from the second buffer chamber 55B into the sensing chamber 56, washing away the recombinant baculovirus 100 or other biomolecules not bound to the antigen Ag, and then flowing to the waste chamber 57. The electronic or optical signals of the first biosensor chip BC1 and the second biosensor chip BC2 are continuously and synchronously detected.

[0344] Step 7: After the reaction reaches equilibrium, the difference between the electronic signal or optical signal generated by the first biosensor chip BC1 and the second biosensor chip BC1 is calculated, which is the electronic signal or optical signal contributed by the antigen Ag (see FIG. 46 or FIG. 55 ).

[0345] In this embodiment, since the recombinant baculovirus 100 simultaneously expresses the reporter protein and protein A, protein G, or a combination of protein A and protein G, the reporter protein on the surface of the recombinant baculovirus 100 can be used as a secondary antibody, and detection can be performed without the need to add or use a secondary antibody or other probe.

[0346] Example 18: Microfluidic System

[0347] The microfluidic system M3 of Example 18 is substantially the same as the microfluidic system M3 of Example 17, except that the envelope of the recombinant baculovirus 100 is provided with a reporter protein and an antibody, rather than a reporter protein and protein A, protein G, or a combination of protein A and protein G (as shown in FIG69 ).

[0348] The following describes the operation process of the microfluidic system M3:

[0349] Step 1: The analyte (blood) enters the sample chamber 52 through the injection port 521 , and the injection port 521 is closed.

[0350] Step 2: The piston or pump located in the first transmission groove 51A pressurizes the air to push the analyte from the sample chamber 52 to the microchannel 54 for red blood cell aggregation and sedimentation. The analyte that has undergone red blood cell aggregation and sedimentation is plasma or serum.

[0351] Step 3: The plasma or serum is pushed into the filtration chamber 53, where the porous membrane filters out any remaining red blood cells or debris. The plasma or serum is then pushed into the sensing chamber 56. Antigens (antibodies) in the plasma or serum bind to the antibodies in the capture layer 561 coated on the first biosensor chip BC1 (as shown in Figures 67 and 68), but do not bind to the second biosensor chip BC2.

[0352] Step 4: The piston or pump located in the second transmission groove 51B pressurizes the air to push the buffer liquid for cleaning from the buffer chamber 55A to the sensing chamber 56, washing away the antigens or other biomolecules not bound to the antibody, and flowing to the waste chamber 57.

[0353] Step 5: Air is pressurized using a piston or pump located in the third transmission channel 51C, pushing the recombinant baculovirus 100 from the virus chamber 58 to the sensing chamber 56. Antibodies on the surface of the recombinant baculovirus 100 bind to the antigen Ag (which has bound to antibodies in the capture layer 561 coated on the first biosensor chip BC1) (as shown in FIG69 ), but do not bind to the second biosensor chip BC2. The electronic or optical signals from the first and second biosensor chips BC1 and BC2 are simultaneously detected. In some embodiments, the optical signal is obtained by detecting the expression of a reporter protein on the surface of the recombinant baculovirus 100.

[0354] Step 6: The piston or pump located in the fourth transmission channel 51D pressurizes the air, pushing the cleaning buffer liquid from the second buffer chamber 55B into the sensing chamber 56, washing away the recombinant baculovirus 100 or other biomolecules not bound to the antigen Ag, and then flowing to the waste chamber 57. The electronic or optical signals of the first biosensor chip BC1 and the second biosensor chip BC2 are continuously and synchronously detected.

[0355] Step 7: After the reaction reaches equilibrium, the difference between the electronic signal or optical signal generated by the first biosensor chip BC1 and the second biosensor chip BC1 is calculated, which is the electronic signal or optical signal contributed by the antigen Ag (see FIG. 46 or FIG. 55 ).

[0356] In this embodiment, since the recombinant baculovirus 100 expresses both the reporter protein and the antibody, the reporter protein on the surface of the recombinant baculovirus 100 can be used as a secondary antibody, and detection can be performed without the need to add or use a secondary antibody or other probes.

[0357] In summary, the recombinant baculovirus plasmid, recombinant baculovirus, detection kit, or microfluidic system according to any embodiment can reduce the development cost of disease detection and identification, shorten the number of operation steps and operation time, and improve the specificity and signal strength of detection. It can also be applied to all applications based on antigen-antibody immune reactions, including disease diagnosis, health examinations, pathogen identification, epidemiological surveys, and scientific research, thereby benefiting social health and scientific development.

[0358] While various embodiments of the present invention have been described above, the above descriptions are intended to be illustrative, non-exhaustive, and not limited to the disclosed embodiments. Many modifications and variations will be apparent to those skilled in the art without departing from the scope and spirit of the described embodiments. The terminology used herein is selected to best explain the principles of the embodiments, their practical applications, or technological improvements in the marketplace, or to enable others skilled in the art to understand the embodiments disclosed herein.

[0359] The above are merely optional embodiments of the present invention and are not intended to limit the present invention. Those skilled in the art will readily appreciate that the present invention is susceptible to various modifications and variations. Any modifications, equivalent substitutions, or improvements made within the spirit and principles of the present invention shall be included within the scope of protection of the present invention.

Claims

1. A recombinant bacmid, characterized in that: include: Baculovirus plasmids; A recombinant expression protein gene is located on the bacmid; and A foreign protein gene is located on the bacmid; Wherein, the recombinant expression protein gene includes: an expression protein gene and a reporter protein gene.

2. The recombinant bacmid according to claim 1, characterized in that The bacmid comprises: Right Tn7 transposon; Left Tn7 transposon; A first promoter is located between the right Tn7 transposon and the left Tn7 transposon; and a second promoter, located between the first promoter and the left Tn7 transposon; Wherein, the recombinant expression protein gene is located between the second promoter and the left Tn7 transposon, and the exogenous protein gene is located between the right Tn7 transposon and the first promoter.

3. The recombinant bacmid according to claim 1, characterized in that The exogenous protein gene is a transmembrane protein gene or a non-transmembrane protein recombinant gene.

4. The recombinant bacmid according to claim 1, characterized in that The exogenous protein gene is a transmembrane protein gene, and the transmembrane protein gene is an antigen gene.

5. The recombinant bacmid according to claim 4, characterized in that The antigen gene is selected from the group consisting of dengue virus antigen gene and Japanese encephalitis virus antigen gene.

6. The recombinant bacmid according to claim 4, characterized in that The antigen gene is selected from the group consisting of a precursor membrane protein gene, a mantle protein gene and a combination thereof.

7. The recombinant bacmid according to claim 1, characterized in that The foreign protein gene is a non-transmembrane protein recombinant gene, which includes a non-transmembrane protein gene and a second expression protein gene. The non-transmembrane protein gene is selected from the group consisting of an antibody, an antigen, a protein A, a protein G, and a combination of the protein A and the protein G.

8. The recombinant bacmid according to claim 7, characterized in that The two ends of the non-transmembrane protein gene are respectively connected to the signal peptide gene of the second expression protein gene and the transmembrane domain gene of the second expression protein gene.

9. The recombinant bacmid according to claim 1, characterized in that The recombinant expression protein gene comprises a signal peptide gene of the expression protein gene, the reporter protein gene, and a transmembrane domain gene of the expression protein gene.

10. The recombinant bacmid according to claim 1, characterized in that The expression protein gene is a baculovirus surface protein gene, and the two ends of the reporter protein gene are respectively connected to the signal peptide gene of the baculovirus surface protein gene and the transmembrane domain gene of the baculovirus surface protein gene.

11. The recombinant bacmid according to claim 1, characterized in that: The reporter protein gene is selected from the group consisting of alkaline phosphatase, fluorescent protein, horseradish peroxidase, luciferase, protein A, protein G, a combination of protein A and protein G, or genes of coloring reaction chemicals.

12. The recombinant bacmid according to claim 2, characterized in that: The first promoter and the second promoter are respectively strong promoters of very late genes.

13. A recombinant baculovirus, characterized in that include: Recombinant baculovirus genes, including: Baculovirus genes; and The recombinant baculovirus plasmid according to any one of claims 1 to 12, wherein the baculovirus gene is embedded; An envelope, encapsulating the recombinant baculovirus gene; and Exogenous proteins and recombinant expression proteins, both of which are disposed on the mantle, wherein the exogenous proteins are selected from the group consisting of antibodies, antigens, protein A, protein G, and a combination of the protein A and the protein G, and the recombinant expression proteins include expression proteins and reporter proteins.

14. A detection kit, characterized in that: include: A well plate, comprising a plurality of reaction wells; Antibodies, coated on the inner surface of each reaction well, are used to bind to target proteins in biological samples; as well as The recombinant baculovirus according to claim 13, wherein the exogenous protein corresponds to a specific protein among the target proteins in the biological sample and is used to bind to the corresponding specific protein.

15. The detection kit according to claim 14, characterized in that: The exogenous protein is the antibody or the antigen, and the specific protein is the antigen or antibody corresponding to the antibody or the antigen.

16. The detection kit according to claim 14, characterized in that: The exogenous protein is protein A, protein G, or a combination of the protein A and the protein G. The exogenous protein binds to an antibody, and the specific protein is an antigen corresponding to the antibody.

17. The detection kit according to claim 14, characterized in that: The titer of the recombinant baculovirus is 10 4 Up to 10 8 Spot forming unit.

18. The detection kit according to claim 14, characterized in that: The antibody is an anti-human immunoglobulin antibody.

19. A microfluidic system, characterized in that: include: Microfluidic module, including: A first transmission groove; A sample chamber connected to the first transmission groove and used to accommodate an object to be tested; Filter chamber; A microchannel, connecting the sample chamber and the filter chamber, and located between the sample chamber and the filter chamber; A second transmission groove; A buffer cavity, connected to the second transmission groove, for accommodating a buffer liquid; A sensing cavity, connected to the filter cavity and the buffer cavity, and located between the filter cavity and the buffer cavity; a capture layer, coated on the inner surface of the sensing cavity, the capture layer comprising: the recombinant baculovirus according to claim 13, wherein the envelope of the recombinant baculovirus is provided with a foreign protein; and A waste cavity is connected to the sensing cavity.

20. The microfluidic system according to claim 19, characterized in that: Also includes: A chipset, located at the bottom of the inner surface of the sensing cavity; Wherein, the exogenous protein is selected from the group consisting of antibodies, antigens, protein A, protein G, and a combination of the protein A and the protein G.

21. The microfluidic system according to claim 20, characterized in that: The chipset comprises: a first biosensor chip and a second biosensor chip, wherein the first biosensor chip is coated with the capture layer, and the second biosensor chip is not coated with the capture layer.

22. The microfluidic system according to claim 19, characterized in that: The microfluidic module also includes: A third transmission slot; and A probe cavity, connected to the third transmission groove and the sensing cavity and located between the third transmission groove and the sensing cavity, the probe cavity being used to accommodate a probe; Wherein, the exogenous protein is selected from the group consisting of antibodies, antigens, protein A, protein G, and a combination of the protein A and the protein G.

23. A microfluidic system, characterized in that: include: Microfluidic module, including: A first transmission groove; A sample chamber connected to the first transmission groove and used to accommodate an object to be tested; Filter chamber; A microchannel, connecting the sample chamber and the filter chamber, and located between the sample chamber and the filter chamber; A second transmission groove; A virus cavity, connected to the second transmission groove, for accommodating the recombinant baculovirus; A reaction chamber, connected to the filter chamber and the virus chamber, and located between the filter chamber and the virus chamber; The third transmission slot; A buffer chamber, connected to the third transmission groove, for accommodating a buffer liquid; A sensing chamber connected to the reaction chamber and the buffer chamber and located between the reaction chamber and the buffer chamber; A capture layer is coated on the inner surface of the sensing cavity, and the capture layer includes an anti- body; and a waste chamber connected to the sensing chamber; and The recombinant baculovirus is the recombinant baculovirus according to claim 13.

24. A microfluidic system, characterized in that: include: Microfluidic module, including: A first transmission groove; A sample chamber connected to the first transmission groove and used to accommodate an object to be tested; Filter chamber; A microchannel, connecting the sample chamber and the filter chamber, and located between the sample chamber and the filter chamber; A second transmission groove; A buffer chamber connected to the second transmission groove and used to accommodate a buffer liquid; The third transmission slot; A virus cavity, connected to the third transmission groove, for accommodating the recombinant baculovirus; A sensing cavity, connected to the filter cavity, the buffer cavity and the virus cavity, and located between the filter cavity, the buffer cavity and the virus cavity; a capture layer, coated on the inner surface of the sensing cavity, comprising antibodies; and a waste chamber connected to the sensing chamber; and The recombinant baculovirus is the recombinant baculovirus according to claim 13.

Citation Information

Patent Citations

  • Microfluidic chip devices and their use

    CN102083533A

  • Expression method for increasing expression quantity of thyroid peroxidase

    CN107841491A

  • Novel baculovirus vectors and methods of use

    CN107921115A

  • Single-index microfluidic chip, and production method and application method thereof

    CN109569754A

  • Portable full-automatic micro-fluidic device and method for detecting quality of fresh water by using portable full-automatic micro-fluidic device

    CN113751090A